<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CELLCEPT- mycophenolate mofetil capsule </strong><br>Cardinal Health<br></p></div>
<h1>
<span class="Bold">CellCept<span class="Sup">®</span></span><br><span class="Bold"> (mycophenolate mofetil capsules) </span><br><span class="Bold">(mycophenolate mofetil tablets) </span><br><br><span class="Bold">CellCept<span class="Sup">®</span> Oral Suspension </span><br><span class="Bold">(mycophenolate mofetil for oral suspension) </span><br><br><span class="Bold">CellCept<span class="Sup">®</span> Intravenous </span><br><span class="Bold">(mycophenolate mofetil hydrochloride for injection) </span><br>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1>WARNING: EMBRYOFETAL TOXICITY, MALIGNANCIES AND SERIOUS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span></h1>
<p class="First"><span class="Bold">Use during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations. Females of reproductive potential (FRP) must be counseled regarding pregnancy prevention and planning (see <a href="#_Ref">WARNINGS</a> and <a href="#_Ref">PRECAUTIONS</a>).</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span> may lead to increased susceptibility to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and possible development of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>. Only physicians experienced in immunosuppressive therapy and management of renal, cardiac or hepatic transplant patients should prescribe CellCept. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient (see <a href="#_Ref">WARNINGS</a> and <a href="#_Ref">PRECAUTIONS</a>).</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_b8341604-45fb-41d3-863c-7a419ee35a34"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">CellCept (mycophenolate mofetil) is the 2-morpholinoethyl ester of mycophenolic acid (MPA), an immunosuppressive agent; inosine monophosphate dehydrogenase (IMPDH) inhibitor.</p>
<p>The chemical name for mycophenolate mofetil (MMF) is 2-morpholinoethyl (E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate. It has an empirical formula of C<span class="Sub">23</span>H<span class="Sub">31</span>NO<span class="Sub">7</span>, a molecular weight of 433.50, and the following structural formula:</p>
<div class="Figure">
<a name="id840"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=81ca6530-76d1-46f1-9bf8-0ffac79d2523&amp;name=cellcept-01.jpg">
</div>
<p>Mycophenolate mofetil is a white to off-white crystalline powder. It is slightly soluble in water (43 µg/mL at pH 7.4); the solubility increases in acidic medium (4.27 mg/mL at pH 3.6). It is freely soluble in acetone, soluble in methanol, and sparingly soluble in ethanol. The apparent partition coefficient in 1-octanol/water (pH 7.4) buffer solution is 238. The pKa values for mycophenolate mofetil are 5.6 for the morpholino group and 8.5 for the phenolic group.</p>
<p>Mycophenolate mofetil hydrochloride has a solubility of 65.8 mg/mL in 5% Dextrose Injection USP (D5W). The pH of the reconstituted solution is 2.4 to 4.1.</p>
<p>CellCept is available for oral administration as capsules containing 250 mg of mycophenolate mofetil, tablets containing 500 mg of mycophenolate mofetil, and as a powder for oral suspension, which when constituted contains 200 mg/mL mycophenolate mofetil.</p>
<p>Inactive ingredients in CellCept 250 mg capsules include croscarmellose sodium, magnesium stearate, povidone (K-90) and pregelatinized starch. The capsule shells contain black iron oxide, FD&amp;C blue #2, gelatin, red iron oxide, silicon dioxide, sodium lauryl sulfate, titanium dioxide, and yellow iron oxide.</p>
<p>Inactive ingredients in CellCept 500 mg tablets include black iron oxide, croscarmellose sodium, FD&amp;C blue #2 aluminum lake, hydroxypropyl cellulose, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol 400, povidone (K-90), red iron oxide, talc, and titanium dioxide; may also contain ammonium hydroxide, ethyl alcohol, methyl alcohol, n-butyl alcohol, propylene glycol, and shellac.</p>
<p>Inactive ingredients in CellCept Oral Suspension include aspartame, citric acid anhydrous, colloidal silicon dioxide, methylparaben, mixed fruit flavor, sodium citrate dihydrate, sorbitol, soybean lecithin, and xanthan gum.</p>
<p>CellCept Intravenous is the hydrochloride salt of mycophenolate mofetil. The chemical name for the hydrochloride salt of mycophenolate mofetil is 2-morpholinoethyl (E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate hydrochloride. It has an empirical formula of C<span class="Sub">23</span>H<span class="Sub">31</span>NO<span class="Sub">7</span> HCl and a molecular weight of 469.96.</p>
<p>CellCept Intravenous is available as a sterile white to off-white lyophilized powder in vials containing mycophenolate mofetil hydrochloride for administration by intravenous infusion only. Each vial of CellCept Intravenous contains the equivalent of 500 mg mycophenolate mofetil as the hydrochloride salt. The inactive ingredients are polysorbate 80, 25 mg, and citric acid, 5 mg. Sodium hydroxide may have been used in the manufacture of CellCept Intravenous to adjust the pH. Reconstitution and dilution with 5% Dextrose Injection USP yields a slightly yellow solution of mycophenolate mofetil, 6 mg/mL. (For detailed method of preparation, see <span class="Bold"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CP"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_58f561c6-59a0-433f-af92-e3175f22070f"></a><a name="section-2.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Mycophenolate mofetil has been demonstrated in experimental animal models to prolong the survival of allogeneic transplants (kidney, heart, liver, intestine, limb, small bowel, pancreatic islets, and bone marrow).</p>
<p>Mycophenolate mofetil has also been shown to reverse ongoing acute rejection in the canine renal and rat cardiac allograft models. Mycophenolate mofetil also inhibited proliferative <span class="product-label-link" type="condition" conceptid="321882" conceptname="Generalized atherosclerosis">arteriopathy</span> in experimental models of aortic and cardiac allografts in rats, as well as in primate cardiac xenografts. Mycophenolate mofetil was used alone or in combination with other immunosuppressive agents in these studies. Mycophenolate mofetil has been demonstrated to inhibit immunologically mediated inflammatory responses in animal models and to inhibit tumor development and prolong survival in murine tumor transplant models.</p>
<p>Mycophenolate mofetil is rapidly absorbed following oral administration and hydrolyzed to form MPA, which is the active metabolite. MPA is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Because T- and B-<span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> are critically dependent for their proliferation on de novo synthesis of purines, whereas other cell types can utilize salvage pathways, MPA has potent cytostatic effects on <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. MPA inhibits proliferative responses of T- and B-<span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> to both mitogenic and allospecific stimulation. Addition of guanosine or deoxyguanosine reverses the cytostatic effects of MPA on <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. MPA also suppresses antibody formation by B-<span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. MPA prevents the glycosylation of lymphocyte and monocyte glycoproteins that are involved in intercellular <span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">adhesion</span> to endothelial cells and may inhibit recruitment of leukocytes into sites of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">graft rejection</span>. Mycophenolate mofetil did not inhibit early events in the activation of human peripheral blood mononuclear cells, such as the production of interleukin-1 (IL-1) and interleukin-2 (IL-2), but did block the coupling of these events to DNA synthesis and proliferation.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Pharmacokinetics"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Following oral and intravenous administration, mycophenolate mofetil undergoes rapid and complete metabolism to MPA, the active metabolite. Oral absorption of the drug is rapid and essentially complete. MPA is metabolized to form the phenolic glucuronide of MPA (MPAG) which is not pharmacologically active. The parent drug, mycophenolate mofetil, can be measured systemically during the intravenous infusion; however, shortly (about 5 minutes) after the infusion is stopped or after oral administration, MMF concentration is below the limit of quantitation (0.4 µg/mL).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e6928c31-29b6-47b6-a80d-ed02f474184e"></a><a name="section-2.2.1"></a><p></p>
<h3><span class="Bold">Absorption</span></h3>
<p class="First">In 12 healthy volunteers, the mean absolute bioavailability of oral mycophenolate mofetil relative to intravenous mycophenolate mofetil (based on MPA AUC) was 94%. The area under the plasma-concentration time curve (AUC) for MPA appears to increase in a dose-proportional fashion in renal transplant patients receiving multiple doses of mycophenolate mofetil up to a daily dose of 3 g (see <span class="Bold"><a href="#_Reftable1">Table 1</a></span>).</p>
<p>Food (27 g fat, 650 calories) had no effect on the extent of absorption (MPA AUC) of mycophenolate mofetil when administered at doses of 1.5 g bid to renal transplant patients. However, MPA C<span class="Sub">max</span> was decreased by 40% in the presence of food (see <span class="Bold"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6775bbf8-6339-4fb3-94d1-11de5b0b258f"></a><a name="section-2.2.2"></a><p></p>
<h3><span class="Bold">Distribution</span></h3>
<p class="First">The mean (±SD) apparent volume of distribution of MPA in 12 healthy volunteers is approximately 3.6 (±1.5) and 4.0 (±1.2) L/kg following intravenous and oral administration, respectively. MPA, at clinically relevant concentrations, is 97% bound to plasma albumin. MPAG is 82% bound to plasma albumin at MPAG concentration ranges that are normally seen in stable renal transplant patients; however, at higher MPAG concentrations (observed in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or delayed renal graft function), the binding of MPA may be reduced as a result of competition between MPAG and MPA for protein binding. Mean blood to plasma ratio of radioactivity concentrations was approximately 0.6 indicating that MPA and MPAG do not extensively distribute into the cellular fractions of blood.</p>
<p>In vitro studies to evaluate the effect of other agents on the binding of MPA to human serum albumin (HSA) or plasma proteins showed that salicylate (at 25 mg/dL with HSA) and MPAG (at ≥460 µg/mL with plasma proteins) increased the free fraction of MPA. At concentrations that exceeded what is encountered clinically, cyclosporine, digoxin, naproxen, prednisone, propranolol, tacrolimus, theophylline, tolbutamide, and warfarin did not increase the free fraction of MPA. MPA at concentrations as high as 100 µg/mL had little effect on the binding of warfarin, digoxin or propranolol, but decreased the binding of theophylline from 53% to 45% and phenytoin from 90% to 87%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8ae701cd-7f68-4649-8bad-004a8612ac81"></a><a name="section-2.2.3"></a><p></p>
<h3><span class="Bold">Metabolism</span></h3>
<p class="First">Following oral and intravenous dosing, mycophenolate mofetil undergoes complete metabolism to MPA, the active metabolite. Metabolism to MPA occurs presystemically after oral dosing. MPA is metabolized principally by glucuronyl transferase to form the phenolic glucuronide of MPA (MPAG) which is not pharmacologically active. In vivo, MPAG is converted to MPA via enterohepatic recirculation. The following metabolites of the 2-hydroxyethyl-morpholino moiety are also recovered in the urine following oral administration of mycophenolate mofetil to healthy subjects: N-(2-carboxymethyl)-morpholine, N-(2-hydroxyethyl)-morpholine, and the N-oxide of N-(2-hydroxyethyl)-morpholine.</p>
<p>Secondary peaks in the plasma MPA concentration-time profile are usually observed 6 to 12 hours postdose. The coadministration of cholestyramine (4 g tid) resulted in approximately a 40% decrease in the MPA AUC (largely as a consequence of lower concentrations in the terminal portion of the profile). These observations suggest that enterohepatic recirculation contributes to MPA plasma concentrations.</p>
<p>Increased plasma concentrations of mycophenolate mofetil metabolites (MPA 50% increase and MPAG about a 3-fold to 6-fold increase) are observed in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (see <span class="Bold"><a href="#CPSP">CLINICAL PHARMACOLOGY: Special Populations</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a16e72c7-2105-475b-96f1-5dfc9a06366b"></a><a name="section-2.2.4"></a><p></p>
<h3><span class="Bold">Excretion</span></h3>
<p class="First">Negligible amount of drug is excreted as MPA (&lt;1% of dose) in the urine. Orally administered radiolabeled mycophenolate mofetil resulted in complete recovery of the administered dose, with 93% of the administered dose recovered in the urine and 6% recovered in feces. Most (about 87%) of the administered dose is excreted in the urine as MPAG. At clinically encountered concentrations, MPA and MPAG are usually not removed by hemodialysis. However, at high MPAG plasma concentrations (&gt;100 µg/mL), small amounts of MPAG are removed. Bile acid sequestrants, such as cholestyramine, reduce MPA AUC by interfering with enterohepatic circulation of the drug (see <span class="Bold"><a href="#OV">OVERDOSAGE</a></span>).</p>
<p>Mean (±SD) apparent half-life and plasma clearance of MPA are 17.9 (±6.5) hours and 193 (±48) mL/min following oral administration and 16.6 (±5.8) hours and 177 (±31) mL/min following intravenous administration, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1625199f-c671-4616-b44b-7446f294ae0f"></a><a name="section-2.2.5"></a><p></p>
<h3><span class="Bold">Pharmacokinetics in Healthy Volunteers, Renal, Cardiac, and Hepatic Transplant Patients</span></h3>
<p class="First">Shown below are the mean (±SD) pharmacokinetic parameters for MPA following the administration of mycophenolate mofetil given as single doses to healthy volunteers and multiple doses to renal, cardiac, and hepatic transplant patients. In the early posttransplant period (&lt;40 days posttransplant), renal, cardiac, and hepatic transplant patients had mean MPA AUCs approximately 20% to 41% lower and mean C<span class="Sub">max</span> approximately 32% to 44% lower compared to the late transplant period (3 to 6 months posttransplant).</p>
<p>Mean MPA AUC values following administration of 1 g bid intravenous mycophenolate mofetil over 2 hours to renal transplant patients for 5 days were about 24% higher than those observed after oral administration of a similar dose in the immediate posttransplant phase. In hepatic transplant patients, administration of 1 g bid intravenous CellCept followed by 1.5 g bid oral CellCept resulted in mean MPA AUC values similar to those found in renal transplant patients administered 1 g CellCept bid.</p>
<a name="_Reftable1"></a><table width="100%">
<caption><span>Table 1 Pharmacokinetic Parameters for MPA [mean (±SD)] Following Administration of Mycophenolate Mofetil to Healthy Volunteers (Single Dose), Renal, Cardiac, and Hepatic Transplant Patients (Multiple Doses)</span></caption>
<col width="26%">
<col width="18%">
<col width="18%">
<col width="18%">
<col width="20%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>AUC(0-12h) values quoted are extrapolated from data from samples collected over 4 hours.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule" valign="middle"><p class="First"><span class="Bold">Dose/Route</span></p></td>
<td class="Botrule Rrule Toprule"><p class="First"><span class="Bold">T<span class="Sub">max</span></span><br><span class="Bold">(h)</span></p></td>
<td class="Botrule Rrule Toprule"><p class="First"><span class="Bold">C<span class="Sub">max</span></span><br><span class="Bold">(µg/mL)</span></p></td>
<td class="Botrule Rrule Toprule"><p class="First"><span class="Bold">Total AUC</span><br><span class="Bold">(µg∙h/mL)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Healthy Volunteers</span><br><span class="Bold"> (single dose)</span></p></td>
<td class="Botrule Rrule"><p class="First">1 g/oral</p></td>
<td class="Botrule Rrule"><p class="First">0.80<br> (±0.36)<br> (n=129)</p></td>
<td class="Botrule Rrule"><p class="First">24.5<br> (±9.5)<br> (n=129)</p></td>
<td class="Botrule Rrule"><p class="First">63.9<br> (±16.2)<br> (n=117)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Renal Transplant Patients (bid dosing) Time After Transplantation</span></p></td>
<td class="Botrule Rrule" valign="middle"><p class="First"><span class="Bold">Dose/Route</span></p></td>
<td class="Botrule Rrule" valign="middle"><p class="First"><span class="Bold">T<span class="Sub">max</span></span><br><span class="Bold"> (h)</span></p></td>
<td class="Botrule Rrule" valign="middle"><p class="First"><span class="Bold">C<span class="Sub">max</span></span><br><span class="Bold"> (µg/mL)</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Interdosing Interval AUC(0-12h)</span><br><span class="Bold"> (µg∙h/mL)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">5 days</p></td>
<td class="Botrule Rrule"><p class="First">1 g/iv</p></td>
<td class="Botrule Rrule"><p class="First">1.58<br> (±0.46)<br> (n=31)</p></td>
<td class="Botrule Rrule"><p class="First">12.0<br> (±3.82)<br> (n=31)</p></td>
<td class="Botrule Rrule"><p class="First">40.8<br> (±11.4)<br> (n=31)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">6 days</p></td>
<td class="Botrule Rrule"><p class="First">1 g/oral</p></td>
<td class="Botrule Rrule"><p class="First">1.33<br> (±1.05)<br> (n=31)</p></td>
<td class="Botrule Rrule"><p class="First">10.7<br> (±4.83)<br> (n=31)</p></td>
<td class="Botrule Rrule"><p class="First">32.9<br> (±15.0)<br> (n=31)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Early (&lt;40 days)</p></td>
<td class="Botrule Rrule"><p class="First">1 g/oral</p></td>
<td class="Botrule Rrule"><p class="First">1.31<br> (±0.76)<br> (n=25)</p></td>
<td class="Botrule Rrule"><p class="First">8.16<br> (±4.50)<br> (n=25)</p></td>
<td class="Botrule Rrule"><p class="First">27.3<br> (±10.9)<br> (n=25)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Early (&lt;40 days)</p></td>
<td class="Botrule Rrule"><p class="First">1.5 g/oral</p></td>
<td class="Botrule Rrule"><p class="First">1.21<br> (±0.81)<br> (n=27)</p></td>
<td class="Botrule Rrule"><p class="First">13.5<br> (±8.18)<br> (n=27)</p></td>
<td class="Botrule Rrule"><p class="First">38.4<br> (±15.4)<br> (n=27)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Late (&gt;3 months)</p></td>
<td class="Botrule Rrule"><p class="First">1.5 g/oral</p></td>
<td class="Botrule Rrule"><p class="First">0.90<br> (±0.24)<br> (n=23)</p></td>
<td class="Botrule Rrule"><p class="First">24.1<br> (±12.1)<br> (n=23)</p></td>
<td class="Botrule Rrule"><p class="First">65.3<br> (±35.4)<br> (n=23)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Cardiac Transplant Patients (bid dosing) Time After Transplantation</span></p></td>
<td class="Botrule Rrule" valign="middle"><p class="First"><span class="Bold">Dose/Route</span></p></td>
<td class="Botrule Rrule" valign="middle"><p class="First"><span class="Bold">T<span class="Sub">max</span></span><br><span class="Bold"> (h)</span></p></td>
<td class="Botrule Rrule" valign="middle"><p class="First"><span class="Bold">C<span class="Sub">max</span></span><br><span class="Bold"> (µg/mL)</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Interdosing Interval AUC(0-12h)</span><br><span class="Bold"> (µg∙h/mL)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Early<br> (Day before discharge)</p></td>
<td class="Botrule Rrule"><p class="First">1.5 g/oral</p></td>
<td class="Botrule Rrule"><p class="First">1.8<br> (±1.3)<br> (n=11)</p></td>
<td class="Botrule Rrule"><p class="First">11.5<br> (±6.8)<br> (n=11)</p></td>
<td class="Botrule Rrule"><p class="First">43.3<br> (±20.8)<br> (n=9)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Late (&gt;6 months)</p></td>
<td class="Botrule Rrule"><p class="First">1.5 g/oral</p></td>
<td class="Botrule Rrule"><p class="First">1.1<br> (±0.7)<br> (n=52)</p></td>
<td class="Botrule Rrule"><p class="First">20.0<br> (±9.4)<br> (n=52)</p></td>
<td class="Botrule Rrule"><p class="First">54.1<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><br> (±20.4)<br> (n=49)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">Hepatic Transplant Patients (bid dosing) Time After Transplantation</span></p></td>
<td class="Botrule Rrule" valign="middle"><p class="First"><span class="Bold">Dose/Route</span></p></td>
<td class="Botrule Rrule" valign="middle"><p class="First"><span class="Bold">T<span class="Sub">max</span></span><br><span class="Bold"> (h)</span></p></td>
<td class="Botrule Rrule" valign="middle"><p class="First"><span class="Bold">C<span class="Sub">max</span></span><br><span class="Bold">(µg/mL)</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Interdosing Interval AUC(0-12h)</span><br><span class="Bold"> (µg∙h/mL)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">4 to 9 days</p></td>
<td class="Botrule Rrule"><p class="First">1 g/iv</p></td>
<td class="Botrule Rrule"><p class="First">1.50<br> (±0.517)<br> (n=22)</p></td>
<td class="Botrule Rrule"><p class="First">17.0<br> (±12.7)<br> (n=22)</p></td>
<td class="Botrule Rrule"><p class="First">34.0<br> (±17.4)<br> (n=22)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Early (5 to 8 days)</p></td>
<td class="Botrule Rrule"><p class="First">1.5 g/oral</p></td>
<td class="Botrule Rrule"><p class="First">1.15<br> (±0.432)<br> (n=20)</p></td>
<td class="Botrule Rrule"><p class="First">13.1<br> (±6.76)<br> (n=20)</p></td>
<td class="Botrule Rrule"><p class="First">29.2<br> (±11.9)<br> (n=20)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Late (&gt;6 months)</p></td>
<td class="Botrule Rrule"><p class="First">1.5 g/oral</p></td>
<td class="Botrule Rrule"><p class="First">1.54<br> (±0.51)<br> (n=6)</p></td>
<td class="Botrule Rrule"><p class="First">19.3<br> (±11.7)<br> (n=6)</p></td>
<td class="Botrule Rrule"><p class="First">49.3<br> (±14.8)<br> (n=6)</p></td>
</tr>
</tbody>
</table>
<p>Two 500 mg tablets have been shown to be bioequivalent to four 250 mg capsules. Five mL of the 200 mg/mL constituted oral suspension have been shown to be bioequivalent to four 250 mg capsules.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="CPSP"></a><a name="section-2.2.6"></a><p></p>
<h3><span class="Bold">Special Populations</span></h3>
<p class="First">Shown below are the mean (±SD) pharmacokinetic parameters for MPA following the administration of oral mycophenolate mofetil given as single doses to non-transplant subjects with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<a name="_Reftable2"></a><table width="100%">
<caption><span>Table 2 Pharmacokinetic Parameters for MPA [mean (±SD)] Following Single Doses of Mycophenolate Mofetil Capsules in Chronic Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></caption>
<col width="26%">
<col width="18%">
<col width="18%">
<col width="18%">
<col width="20%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span><br><span class="Bold"> (no. of patients)</span></p></td>
<td class="Botrule Rrule Toprule" valign="middle"><p class="First"><span class="Bold">Dose</span></p></td>
<td class="Botrule Rrule Toprule" valign="middle"><p class="First"><span class="Bold">T<span class="Sub">max</span></span><br><span class="Bold"> (h)</span></p></td>
<td class="Botrule Rrule Toprule" valign="middle"><p class="First"><span class="Bold">C<span class="Sub">max</span></span><br><span class="Bold"> (µg/mL)</span></p></td>
<td class="Botrule Rrule Toprule" valign="middle"><p class="First"><span class="Bold">AUC(0-96h)</span><br><span class="Bold"> (µg∙h/mL)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Healthy Volunteers<br>  GFR &gt;80 mL/min/1.73 m<span class="Sup">2</span><br>  (n=6)</p></td>
<td class="Botrule Rrule"><p class="First">1 g</p></td>
<td class="Botrule Rrule"><p class="First">0.75<br>(±0.27)</p></td>
<td class="Botrule Rrule"><p class="First">25.3<br>(±7.99)</p></td>
<td class="Botrule Rrule"><p class="First">45.0<br>(±22.6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span><br>  GFR 50 to 80 mL/min/1.73 m<span class="Sup">2</span><br>  (n=6)</p></td>
<td class="Botrule Rrule"><p class="First">1 g</p></td>
<td class="Botrule Rrule"><p class="First">0.75<br>(±0.27)</p></td>
<td class="Botrule Rrule"><p class="First">26.0<br>(±3.82)</p></td>
<td class="Botrule Rrule"><p class="First">59.9<br>(±12.9)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span><br>  GFR 25 to 49 mL/min/1.73 m<span class="Sup">2</span><br>  (n=6)</p></td>
<td class="Botrule Rrule"><p class="First">1 g</p></td>
<td class="Botrule Rrule"><p class="First">0.75<br>(±0.27)</p></td>
<td class="Botrule Rrule"><p class="First">19.0<br>(±13.2)</p></td>
<td class="Botrule Rrule"><p class="First">52.9<br>(±25.5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span><br>  GFR &lt;25 mL/min/1.73 m<span class="Sup">2</span><br>  (n=7)</p></td>
<td class="Botrule Rrule"><p class="First">1 g</p></td>
<td class="Botrule Rrule"><p class="First">1.00<br>(±0.41)</p></td>
<td class="Botrule Rrule"><p class="First">16.3<br>(±10.8)</p></td>
<td class="Botrule Rrule"><p class="First">78.6<br>(±46.4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span><br><span class="Bold"> (no. of patients)</span></p></td>
<td class="Botrule Rrule" valign="middle"><p class="First"><span class="Bold">Dose</span></p></td>
<td class="Botrule Rrule" valign="middle"><p class="First"><span class="Bold">T<span class="Sub">max</span></span><br><span class="Bold"> (h)</span></p></td>
<td class="Botrule Rrule" valign="middle"><p class="First"><span class="Bold">C<span class="Sub">max</span></span><br><span class="Bold"> (µg/mL)</span></p></td>
<td class="Botrule Rrule" valign="middle"><p class="First"><span class="Bold">AUC(0-48h)</span><br><span class="Bold"> (µg∙h/mL)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Healthy Volunteers<br>  (n=6)</p></td>
<td class="Botrule Rrule"><p class="First">1 g</p></td>
<td class="Botrule Rrule"><p class="First">0.63<br>(±0.14)</p></td>
<td class="Botrule Rrule"><p class="First">24.3<br>(±5.73)</p></td>
<td class="Botrule Rrule"><p class="First">29.0<br>(±5.78)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="196463" conceptname="Alcoholic cirrhosis">Alcoholic Cirrhosis</span><br>  (n=18)</p></td>
<td class="Botrule Rrule"><p class="First">1 g</p></td>
<td class="Botrule Rrule"><p class="First">0.85<br>(±0.58)</p></td>
<td class="Botrule Rrule"><p class="First">22.4<br>(±10.1)</p></td>
<td class="Botrule Rrule"><p class="First">29.8<br>(±10.7)</p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a4d865ce-4596-4f57-afe8-4945046f8437"></a><a name="section-2.2.6.1"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></p>
<p>In a single-dose study, MMF was administered as capsule or intravenous infusion over 40 minutes. Plasma MPA AUC observed after oral dosing to volunteers with severe <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic renal impairment</span> [glomerular filtration rate (GFR) &lt;25 mL/min/1.73 m<span class="Sup">2</span>] was about 75% higher relative to that observed in healthy volunteers (GFR &gt;80 mL/min/1.73 m<span class="Sup">2</span>). In addition, the single-dose plasma MPAG AUC was 3-fold to 6-fold higher in volunteers with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> than in volunteers with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or healthy volunteers, consistent with the known renal elimination of MPAG. No data are available on the safety of long-term exposure to this level of MPAG.</p>
<p>Plasma MPA AUC observed after single-dose (1 g) intravenous dosing to volunteers (n=4) with severe <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic renal impairment</span> (GFR &lt;25 mL/min/1.73 m<span class="Sup">2</span>) was 62.4 µg∙h/mL (±19.3). Multiple dosing of mycophenolate mofetil in patients with severe <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic renal impairment</span> has not been studied (see <span class="Bold"><a href="#PreRenal">PRECAUTIONS: Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></span> and <span class="Bold"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>In patients with delayed renal graft function posttransplant, mean MPA AUC(0-12h) was comparable to that seen in posttransplant patients without delayed renal graft function. There is a potential for a transient increase in the free fraction and concentration of plasma MPA in patients with delayed renal graft function. However, dose adjustment does not appear to be necessary in patients with delayed renal graft function. Mean plasma MPAG AUC(0-12h) was 2-fold to 3-fold higher than in posttransplant patients without delayed renal graft function (see <span class="Bold"><a href="#PreRenal">PRECAUTIONS: Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></span> and <span class="Bold"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>In 8 patients with primary graft non-function following renal transplantation, plasma concentrations of MPAG accumulated about 6-fold to 8-fold after multiple dosing for 28 days. Accumulation of MPA was about 1-fold to 2-fold.</p>
<p>The pharmacokinetics of mycophenolate mofetil are not altered by hemodialysis. Hemodialysis usually does not remove MPA or MPAG. At high concentrations of MPAG (&gt;100 µg/mL), hemodialysis removes only small amounts of MPAG.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_eddeb175-9d6a-43f9-9af0-9ddffe528277"></a><a name="section-2.2.6.2"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></p>
<p>In a single-dose (1 g oral) study of 18 volunteers with <span class="product-label-link" type="condition" conceptid="196463" conceptname="Alcoholic cirrhosis">alcoholic cirrhosis</span> and 6 healthy volunteers, hepatic MPA glucuronidation processes appeared to be relatively unaffected by hepatic parenchymal disease when pharmacokinetic parameters of healthy volunteers and <span class="product-label-link" type="condition" conceptid="196463" conceptname="Alcoholic cirrhosis">alcoholic cirrhosis</span> patients within this study were compared. However, it should be noted that for unexplained reasons, the healthy volunteers in this study had about a 50% lower AUC as compared to healthy volunteers in other studies, thus making comparisons between volunteers with <span class="product-label-link" type="condition" conceptid="196463" conceptname="Alcoholic cirrhosis">alcoholic cirrhosis</span> and healthy volunteers difficult. Effects of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> on this process probably depend on the particular disease. <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic disease</span> with other etiologies, such as <span class="product-label-link" type="condition" conceptid="4135822" conceptname="Primary biliary cirrhosis">primary biliary cirrhosis</span>, may show a different effect. In a single-dose (1 g intravenous) study of 6 volunteers with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (aminopyrine breath test less than 0.2% of dose) due to <span class="product-label-link" type="condition" conceptid="196463" conceptname="Alcoholic cirrhosis">alcoholic cirrhosis</span>, MMF was rapidly converted to MPA. MPA AUC was 44.1 µg∙h/mL (±15.5).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7a297a3c-ad3b-4048-a298-3edc9cbaaefe"></a><a name="section-2.2.6.3"></a><p></p>
<p class="First">Pediatrics</p>
<p>The pharmacokinetic parameters of MPA and MPAG have been evaluated in 55 pediatric patients (ranging from 1 year to 18 years of age) receiving CellCept oral suspension at a dose of 600 mg/m<span class="Sup">2</span> bid (up to a maximum of 1 g bid) after allogeneic renal transplantation. The pharmacokinetic data for MPA is provided in <span class="Bold"><a href="#_Reftable3">Table 3</a></span>.</p>
<a name="_Reftable3"></a><table width="100%">
<caption><span>Table 3 Mean (±SD) Computed Pharmacokinetic Parameters for MPA by Age and Time After Allogeneic Renal Transplantation</span></caption>
<col width="15%">
<col width="10%">
<col width="15%">
<col width="10%">
<col width="10%">
<col width="10%">
<col width="10%">
<col width="10%">
<col width="10%">
<thead><tr class="First Last">
<th class="Botrule Lrule Toprule" align="left" valign="middle"><span class="Bold">Age Group</span></th>
<th class="Botrule Rrule Toprule" align="left" valign="middle"><span class="Bold">(n)</span></th>
<th class="Botrule Rrule Toprule" align="left" valign="middle"><span class="Bold">Time</span></th>
<th class="Botrule Rrule Toprule" align="left" colspan="2" valign="middle">
<span class="Bold">T<span class="Sub">max</span></span><br><span class="Bold">  (h)</span>
</th>
<th class="Botrule Rrule Toprule" align="left" colspan="2" valign="middle">
<span class="Bold">Dose Adjusted</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a><br><span class="Bold">C<span class="Sub">max</span></span><br><span class="Bold">(µg/mL)</span>
</th>
<th class="Botrule Rrule Toprule" align="left" colspan="2" valign="middle">
<span class="Bold">Dose Adjusted</span><a href="#footnote-2" class="Sup">*</a><br><span class="Bold">AUC<span class="Sub">0-12</span></span><br><span class="Bold">  (µg∙h/mL)</span>
</th>
</tr></thead>
<tfoot><tr><td colspan="9" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>adjusted to a dose of 600 mg/m<span class="Bold"><span class="Sup">2</span></span>
</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">†</a></dt>
<dd>a subset of 1 to &lt;6 yr</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">‡</a></dt>
<dd>n=20</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">§</a></dt>
<dd>n=16</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Toprule"></td>
<td class="Rrule Toprule"></td>
<td class="Rrule Toprule"><p class="First">Early (Day 7)</p></td>
<td class="Toprule"></td>
<td class="Rrule Toprule"></td>
<td class="Toprule"></td>
<td class="Rrule Toprule"></td>
<td class="Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><br>1 to &lt;2 yr</p></td>
<td class="Rrule"><p class="First">(6)<a name="footnote-reference-3" href="#footnote-3" class="Sup">†</a></p></td>
<td class="Rrule"></td>
<td><p class="First">3.03</p></td>
<td class="Rrule"><p class="First">(4.70)</p></td>
<td><p class="First">10.3</p></td>
<td class="Rrule"><p class="First">(5.80)</p></td>
<td><p class="First">22.5</p></td>
<td class="Rrule"><p class="First">(6.66)<br></p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">1 to &lt;6 yr</p></td>
<td class="Rrule"><p class="First">(17)</p></td>
<td class="Rrule"></td>
<td><p class="First">1.63</p></td>
<td class="Rrule"><p class="First">(2.85)</p></td>
<td><p class="First">13.2</p></td>
<td class="Rrule"><p class="First">(7.16)</p></td>
<td><p class="First">27.4</p></td>
<td class="Rrule"><p class="First">(9.54)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">6 to &lt;12 yr</p></td>
<td class="Rrule"><p class="First">(16)</p></td>
<td class="Rrule"></td>
<td><p class="First">0.940</p></td>
<td class="Rrule"><p class="First">(0.546)</p></td>
<td><p class="First">13.1</p></td>
<td class="Rrule"><p class="First">(6.30)</p></td>
<td><p class="First">33.2</p></td>
<td class="Rrule"><p class="First">(12.1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">12 to 18 yr</p></td>
<td class="Botrule Rrule"><p class="First">(21)</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"><p class="First">1.16</p></td>
<td class="Botrule Rrule"><p class="First">(0.830)</p></td>
<td class="Botrule"><p class="First">11.7</p></td>
<td class="Botrule Rrule"><p class="First">(10.7)</p></td>
<td class="Botrule"><p class="First">26.3</p></td>
<td class="Botrule Rrule"><p class="First">(9.14)<a name="footnote-reference-4" href="#footnote-4" class="Sup">‡</a></p></td>
</tr>
<tr>
<td class="Lrule"></td>
<td class="Rrule"></td>
<td class="Rrule"><p class="First">Late (Month 3)</p></td>
<td></td>
<td class="Rrule"></td>
<td></td>
<td class="Rrule"></td>
<td></td>
<td class="Rrule"></td>
</tr>
<tr>
<td class="Lrule"><p class="First">1 to &lt;2 yr</p></td>
<td class="Rrule"><p class="First">(4)<a href="#footnote-3" class="Sup">†</a></p></td>
<td class="Rrule"></td>
<td><p class="First">0.725</p></td>
<td class="Rrule"><p class="First">(0.276)</p></td>
<td><p class="First">23.8</p></td>
<td class="Rrule"><p class="First">(13.4)</p></td>
<td><p class="First">47.4</p></td>
<td class="Rrule"><p class="First">(14.7)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">1 to &lt;6 yr</p></td>
<td class="Rrule"><p class="First">(15)</p></td>
<td class="Rrule"></td>
<td><p class="First">0.989</p></td>
<td class="Rrule"><p class="First">(0.511)</p></td>
<td><p class="First">22.7</p></td>
<td class="Rrule"><p class="First">(10.1)</p></td>
<td><p class="First">49.7</p></td>
<td class="Rrule"><p class="First">(18.2)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">6 to &lt;12 yr</p></td>
<td class="Rrule"><p class="First">(14)</p></td>
<td class="Rrule"></td>
<td><p class="First">1.21</p></td>
<td class="Rrule"><p class="First">(0.532)</p></td>
<td><p class="First">27.8</p></td>
<td class="Rrule"><p class="First">(14.3)</p></td>
<td><p class="First">61.9</p></td>
<td class="Rrule"><p class="First">(19.6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">12 to 18 yr</p></td>
<td class="Botrule Rrule"><p class="First">(17)</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"><p class="First">0.978</p></td>
<td class="Botrule Rrule"><p class="First">(0.484)</p></td>
<td class="Botrule"><p class="First">17.9</p></td>
<td class="Botrule Rrule"><p class="First">(9.57)</p></td>
<td class="Botrule"><p class="First">53.6</p></td>
<td class="Botrule Rrule"><p class="First">(20.3)<a name="footnote-reference-5" href="#footnote-5" class="Sup">§</a></p></td>
</tr>
<tr>
<td class="Lrule"></td>
<td class="Rrule"></td>
<td class="Rrule"><p class="First">Late (Month 9)</p></td>
<td></td>
<td class="Rrule"></td>
<td></td>
<td class="Rrule"></td>
<td></td>
<td class="Rrule"></td>
</tr>
<tr>
<td class="Lrule"><p class="First">1 to &lt;2 yr</p></td>
<td class="Rrule"><p class="First">(4)<a href="#footnote-3" class="Sup">†</a></p></td>
<td class="Rrule"></td>
<td><p class="First">0.604</p></td>
<td class="Rrule"><p class="First">(0.208)</p></td>
<td><p class="First">25.6</p></td>
<td class="Rrule"><p class="First">(4.25)</p></td>
<td><p class="First">55.8</p></td>
<td class="Rrule"><p class="First">(11.6)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">1 to &lt;6 yr</p></td>
<td class="Rrule"><p class="First">(12)</p></td>
<td class="Rrule"></td>
<td><p class="First">0.869</p></td>
<td class="Rrule"><p class="First">(0.479)</p></td>
<td><p class="First">30.4</p></td>
<td class="Rrule"><p class="First">(9.16)</p></td>
<td><p class="First">61.0</p></td>
<td class="Rrule"><p class="First">(10.7)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">6 to &lt;12 yr</p></td>
<td class="Rrule"><p class="First">(11)</p></td>
<td class="Rrule"></td>
<td><p class="First">1.12</p></td>
<td class="Rrule"><p class="First">(0.462)</p></td>
<td><p class="First">29.2</p></td>
<td class="Rrule"><p class="First">(12.6)</p></td>
<td><p class="First">66.8</p></td>
<td class="Rrule"><p class="First">(21.2)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">12 to 18 yr</p></td>
<td class="Botrule Rrule"><p class="First">(14)</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"><p class="First">1.09</p></td>
<td class="Botrule Rrule"><p class="First">(0.518)</p></td>
<td class="Botrule"><p class="First">18.1</p></td>
<td class="Botrule Rrule"><p class="First">(7.29)</p></td>
<td class="Botrule"><p class="First">56.7</p></td>
<td class="Botrule Rrule"><p class="First">(14.0)</p></td>
</tr>
</tbody>
</table>
<p>The CellCept oral suspension dose of 600 mg/m<span class="Sup">2</span> bid (up to a maximum of 1 g bid) achieved mean MPA AUC values in pediatric patients similar to those seen in adult renal transplant patients receiving CellCept capsules at a dose of 1 g bid in the early posttransplant period. There was wide variability in the data. As observed in adults, early posttransplant MPA AUC values were approximately 45% to 53% lower than those observed in the later posttransplant period (&gt;3 months). MPA AUC values were similar in the early and late posttransplant period across the 1 year to 18 year age range.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_afcb1772-82e8-40d3-a912-fab0c3a46f97"></a><a name="section-2.2.6.4"></a><p></p>
<p class="First">Gender</p>
<p>Data obtained from several studies were pooled to look at any gender-related differences in the pharmacokinetics of MPA (data were adjusted to 1 g oral dose). Mean (±SD) MPA AUC(0-12h) for males (n=79) was 32.0 (±14.5) and for females (n=41) was 36.5 (±18.8) µg∙h/mL while mean (±SD) MPA C<span class="Sub">max</span> was 9.96 (±6.19) in the males and 10.6 (±5.64) µg/mL in the females. These differences are not of clinical significance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4151094e-ab86-499c-bd45-69b4a13d42ce"></a><a name="section-2.2.6.5"></a><p></p>
<p class="First">Geriatrics</p>
<p>Pharmacokinetics in the elderly have not been studied.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="CS"></a><a name="section-3"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b9b11c0e-15e5-4a04-a2b9-232aa60d9acc"></a><a name="section-3.1"></a><p></p>
<h2>Adults</h2>
<p class="First">The safety and efficacy of CellCept in combination with corticosteroids and cyclosporine for the prevention of organ rejection were assessed in randomized, double-blind, multicenter trials in renal (3 trials), in cardiac (1 trial), and in hepatic (1 trial) adult transplant patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2df25706-b686-4135-abca-7765ec34fbad"></a><a name="section-3.2"></a><p></p>
<h2>Renal Transplant</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_52dc56ac-5b80-4afd-8e1a-9c5b69f14b31"></a><a name="section-3.2.1"></a><p></p>
<p class="First"><span class="Italics">Adults</span></p>
<p>The three renal studies compared two dose levels of oral CellCept (1 g bid and 1.5 g bid) with azathioprine (2 studies) or placebo (1 study) when administered in combination with cyclosporine (Sandimmune<span class="Sup">®</span>) and corticosteroids to prevent acute rejection episodes. One study also included antithymocyte globulin (ATGAM<span class="Sup">®</span>) induction therapy. These studies are described by geographic location of the investigational sites. One study was conducted in the USA at 14 sites, one study was conducted in Europe at 20 sites, and one study was conducted in Europe, Canada, and Australia at a total of 21 sites.</p>
<p>The primary efficacy endpoint was the proportion of patients in each treatment group who experienced treatment failure within the first 6 months after transplantation (defined as biopsy-proven acute rejection on treatment or the occurrence of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, graft loss or early termination from the study for any reason without prior biopsy-proven rejection). CellCept, when administered with antithymocyte globulin (ATGAM<span class="Sup">®</span>) induction (one study) and with cyclosporine and corticosteroids (all three studies), was compared to the following three therapeutic regimens: (1) antithymocyte globulin (ATGAM<span class="Sup">®</span>) induction/azathioprine/cyclosporine/corticosteroids, (2) azathioprine/cyclosporine/corticosteroids, and (3) cyclosporine/corticosteroids.</p>
<p>CellCept, in combination with corticosteroids and cyclosporine reduced (statistically significant at 0.05 level) the incidence of treatment failure within the first 6 months following transplantation. <span class="Bold"><a href="#_Reftable4">Table 4</a></span> and <span class="Bold"><a href="#_Reftable5">Table 5</a></span> summarize the results of these studies. These tables show (1) the proportion of patients experiencing treatment failure, (2) the proportion of patients who experienced biopsy-proven acute rejection on treatment, and (3) early termination, for any reason other than graft loss or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, without a prior biopsy-proven acute rejection episode. Patients who prematurely discontinued treatment were followed for the occurrence of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or graft loss, and the cumulative incidence of graft loss and patient <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> are summarized separately. Patients who prematurely discontinued treatment were not followed for the occurrence of acute rejection after termination. More patients receiving CellCept discontinued without prior biopsy-proven rejection, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or graft loss than discontinued in the control groups, with the highest rate in the CellCept 3 g/day group. Therefore, the acute rejection rates may be underestimates, particularly in the CellCept 3 g/day group.</p>
<a name="_Reftable4"></a><table width="100%">
<caption><span>Table 4 Renal Transplant Studies</span></caption>
<col width="25%">
<col width="25%">
<col width="25%">
<col width="25%">
<thead><tr class="First Last"><th class="Botrule Toprule" align="center" colspan="4" valign="top"><span class="Bold">Incidence of Treatment Failure (Biopsy-proven Rejection or Early Termination for Any Reason)</span></th></tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Antithymocyte globulin induction/MMF or azathioprine/cyclosporine/corticosteroids.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd>Does not include <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and graft loss as reason for early termination.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">‡</a></dt>
<dd>MMF or azathioprine/cyclosporine/corticosteroids.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">§</a></dt>
<dd>MMF or placebo/cyclosporine/corticosteroids.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">USA Study</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a><br><br><span class="Bold">(N=499 patients)</span></p></td>
<td class="Botrule Rrule Toprule"><p class="First"><span class="Bold">CellCept</span><br><span class="Bold"> 2 g/day</span><br><span class="Bold">(n=167 patients)</span></p></td>
<td class="Botrule Rrule Toprule"><p class="First"><span class="Bold">CellCept</span><br><span class="Bold"> 3 g/day</span><br><span class="Bold">(n=166 patients)</span></p></td>
<td class="Botrule Rrule Toprule"><p class="First"><span class="Bold">Azathioprine</span><br><span class="Bold"> 1 to 2 mg/kg/day</span><br><span class="Bold">(n=166 patients)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">All treatment failures</p></td>
<td class="Botrule Rrule"><p class="First">31.1%</p></td>
<td class="Botrule Rrule"><p class="First">31.3%</p></td>
<td class="Botrule Rrule"><p class="First">47.6%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Early termination without prior acute rejection<a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a></p></td>
<td class="Botrule Rrule"><p class="First">9.6%</p></td>
<td class="Botrule Rrule"><p class="First">12.7%</p></td>
<td class="Botrule Rrule"><p class="First">6.0%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Biopsy-proven rejection episode on treatment</p></td>
<td class="Rrule"><p class="First">19.8%</p></td>
<td class="Rrule"><p class="First">17.5%</p></td>
<td class="Rrule"><p class="First">38.0%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Europe/Canada/</span><br><span class="Bold"> Australia Study</span><a name="footnote-reference-8" href="#footnote-8" class="Sup">‡</a><br><span class="Bold"> (N=503 patients)</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">CellCept</span><br><span class="Bold">2 g/day</span><br><span class="Bold">(n=173 patients)</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">CellCept</span><br><span class="Bold">3 g/day</span><br><span class="Bold">(n=164 patients)</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Azathioprine</span><br><span class="Bold">100 to 150 mg/day</span><br><span class="Bold"> (n=166 patients)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">All treatment failures</p></td>
<td class="Botrule Rrule"><p class="First">38.2%</p></td>
<td class="Botrule Rrule"><p class="First">34.8%</p></td>
<td class="Botrule Rrule"><p class="First">50.0%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Early termination without prior acute rejection<a href="#footnote-7" class="Sup">†</a></p></td>
<td class="Botrule Rrule"><p class="First">13.9%</p></td>
<td class="Botrule Rrule"><p class="First">15.2%</p></td>
<td class="Botrule Rrule"><p class="First">10.2%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Biopsy-proven rejection episode on treatment</p></td>
<td class="Rrule"><p class="First">19.7%</p></td>
<td class="Rrule"><p class="First">15.9%</p></td>
<td class="Rrule"><p class="First">35.5%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Europe Study</span><a name="footnote-reference-9" href="#footnote-9" class="Sup">§</a><br><br><span class="Bold"> (N=491 patients)</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">CellCept</span><br><span class="Bold">2 g/day</span><br><span class="Bold">(n=165 patients)</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">CellCept</span><br><span class="Bold">3 g/day</span><br><span class="Bold">(n=160 patients)</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Placebo</span><br><br><span class="Bold"> (n=166 patients)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">All treatment failures</p></td>
<td class="Botrule Rrule"><p class="First">30.3%</p></td>
<td class="Botrule Rrule"><p class="First">38.8%</p></td>
<td class="Botrule Rrule"><p class="First">56.0%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Early termination without prior acute rejection<a href="#footnote-7" class="Sup">†</a></p></td>
<td class="Botrule Rrule"><p class="First">11.5%</p></td>
<td class="Botrule Rrule"><p class="First">22.5%</p></td>
<td class="Botrule Rrule"><p class="First">7.2%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Biopsy-proven rejection episode on treatment</p></td>
<td class="Botrule Rrule"><p class="First">17.0%</p></td>
<td class="Botrule Rrule"><p class="First">13.8%</p></td>
<td class="Botrule Rrule"><p class="First">46.4%</p></td>
</tr>
</tbody>
</table>
<p>The cumulative incidence of 12-month graft loss or patient <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> is presented below. No advantage of CellCept with respect to graft loss or patient <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was established. Numerically, patients receiving CellCept 2 g/day and 3 g/day experienced a better outcome than controls in all three studies; patients receiving CellCept 2 g/day experienced a better outcome than CellCept 3 g/day in two of the three studies. Patients in all treatment groups who terminated treatment early were found to have a poor outcome with respect to graft loss or patient <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> at 1 year.</p>
<a name="_Reftable5"></a><table width="100%">
<caption><span>Table 5 Renal Transplant Studies</span></caption>
<col width="25%">
<col width="25%">
<col width="25%">
<col width="25%">
<thead>
<tr class="First"><th class="Botrule Toprule" align="center" colspan="4" valign="top"><span class="Bold">Cumulative Incidence of Combined Graft Loss or Patient <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> at 12 Months</span></th></tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Study</span></th>
<th class="Botrule Rrule" align="left" valign="top">
<span class="Bold">CellCept</span><br><span class="Bold">2 g/day</span>
</th>
<th class="Botrule Rrule" align="left" valign="top">
<span class="Bold">CellCept</span><br><span class="Bold">3 g/day</span>
</th>
<th class="Botrule Rrule" align="left" valign="top">
<span class="Bold">Control</span><br><span class="Bold">(Azathioprine or Placebo)</span>
</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First">USA</p></td>
<td class="Botrule Rrule Toprule"><p class="First">8.5%</p></td>
<td class="Botrule Rrule Toprule"><p class="First">11.5%</p></td>
<td class="Botrule Rrule Toprule"><p class="First">12.2%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Europe/Canada/Australia</p></td>
<td class="Botrule Rrule"><p class="First">11.7%</p></td>
<td class="Botrule Rrule"><p class="First">11.0%</p></td>
<td class="Botrule Rrule"><p class="First">13.6%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Europe</p></td>
<td class="Botrule Rrule"><p class="First">8.5%</p></td>
<td class="Botrule Rrule"><p class="First">10.0%</p></td>
<td class="Botrule Rrule"><p class="First">11.5%</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_756dfd14-edd0-4174-8904-1cb1a15a2b48"></a><a name="section-3.2.2"></a><p></p>
<p class="First"><span class="Italics">Pediatrics</span></p>
<p>One open-label, safety and pharmacokinetic study of CellCept oral suspension 600 mg/m<span class="Sup">2</span> bid (up to 1 g bid) in combination with cyclosporine and corticosteroids was performed at centers in the US (9), Europe (5) and Australia (1) in 100 pediatric patients (3 months to 18 years of age) for the prevention of renal allograft rejection. CellCept was well tolerated in pediatric patients (see <span class="Bold"><a href="#AR">ADVERSE REACTIONS</a></span>), and the pharmacokinetics profile was similar to that seen in adult patients dosed with 1 g bid CellCept capsules (see <span class="Bold"><a href="#Pharmacokinetics">CLINICAL PHARMACOLOGY: Pharmacokinetics</a></span>). The rate of biopsy-proven rejection was similar across the age groups (3 months to &lt;6 years, 6 years to &lt;12 years, 12 years to 18 years). The overall biopsy-proven rejection rate at 6 months was comparable to adults. The combined incidence of graft loss (5%) and patient <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (2%) at 12 months posttransplant was similar to that observed in adult renal transplant patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7832be01-3c42-4eaa-8766-1824e94d25b1"></a><a name="section-3.3"></a><p></p>
<h2>Cardiac Transplant</h2>
<p class="First">A double-blind, randomized, comparative, parallel-group, multicenter study in primary cardiac transplant recipients was performed at 20 centers in the United States, 1 in Canada, 5 in Europe and 2 in Australia. The total number of patients enrolled was 650; 72 never received study drug and 578 received study drug. Patients received CellCept 1.5 g bid (n=289) or azathioprine 1.5 to 3 mg/kg/day (n=289), in combination with cyclosporine (Sandimmune<span class="Sup">®</span> or Neoral<span class="Sup">®</span>) and corticosteroids as maintenance immunosuppressive therapy. The two primary efficacy endpoints were: (1) the proportion of patients who, after transplantation, had at least one endomyocardial biopsy-proven rejection with hemodynamic compromise, or were retransplanted or died, within the first 6 months, and (2) the proportion of patients who died or were retransplanted during the first 12 months following transplantation. Patients who prematurely discontinued treatment were followed for the occurrence of allograft rejection for up to 6 months and for the occurrence of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> for 1 year.</p>
<p><span class="Italics">(1) Rejection:</span> No difference was established between CellCept and azathioprine (AZA) with respect to biopsy-proven rejection with hemodynamic compromise.</p>
<p><span class="Italics">(2) Survival:</span> CellCept was shown to be at least as effective as AZA in preventing <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or retransplantation at 1 year (see <span class="Bold"><a href="#_Reftable6">Table 6</a></span>).</p>
<a name="_Reftable6"></a><table width="100%">
<caption><span>Table 6 Rejection at 6 Months/<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> or Retransplantation at 1 Year</span></caption>
<col width="28%">
<col width="26%">
<col width="15%">
<col width="15%">
<col width="15%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"></th>
<th class="Botrule Rrule Toprule" align="left" colspan="2" valign="top"><span class="Bold">All Patients</span></th>
<th class="Botrule Rrule Toprule" align="left" colspan="2" valign="top"><span class="Bold">Treated Patients</span></th>
</tr>
<tr class="Last">
<th class="Botrule Rrule" align="center" valign="top">
<span class="Bold">AZA</span><br><span class="Bold"> N = 323</span>
</th>
<th class="Botrule Rrule" align="left" valign="top">
<span class="Bold">CellCept</span><br><span class="Bold"> N = 327</span>
</th>
<th class="Botrule Rrule" align="left" valign="top">
<span class="Bold">AZA</span><br><span class="Bold"> N = 289</span>
</th>
<th class="Botrule Rrule" align="left" valign="top">
<span class="Bold">CellCept</span><br><span class="Bold"> N = 289</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-10" href="#footnote-reference-10">*</a></dt>
<dd>Hemodynamic compromise occurred if any of the following criteria were met: pulmonary capillary wedge pressure ≥20 mm or a 25% increase; <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> &lt;2.0 L/min/m<span class="Sup">2</span> or a 25% decrease; <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> ≤30%; pulmonary artery oxygen saturation ≤60% or a 25% decrease; presence of new S<span class="Sub">3</span> gallop; fractional shortening was ≤20% or a 25% decrease; inotropic support required to manage the clinical condition.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Biopsy-proven rejection with hemodynamic compromise at 6 months<a name="footnote-reference-10" href="#footnote-10" class="Sup">*</a></p></td>
<td class="Botrule Rrule Toprule"><p class="First">121 (38%)</p></td>
<td class="Botrule Rrule Toprule"><p class="First">120 (37%)</p></td>
<td class="Botrule Rrule Toprule"><p class="First">100 (35%)</p></td>
<td class="Botrule Rrule Toprule"><p class="First">92 (32%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> or retransplantation at 1 year</p></td>
<td class="Botrule Rrule"><p class="First">49 (15.2%)</p></td>
<td class="Botrule Rrule"><p class="First">42 (12.8%)</p></td>
<td class="Botrule Rrule"><p class="First">33 (11.4%)</p></td>
<td class="Botrule Rrule"><p class="First">18 (6.2%)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cdaaebe1-64bf-48d1-abc5-0f2f526ea9cf"></a><a name="section-3.4"></a><p></p>
<h2>Hepatic Transplant</h2>
<p class="First">A double-blind, randomized, comparative, parallel-group, multicenter study in primary hepatic transplant recipients was performed at 16 centers in the United States, 2 in Canada, 4 in Europe and 1 in Australia. The total number of patients enrolled was 565. Per protocol, patients received CellCept 1 g bid intravenously for up to 14 days followed by CellCept 1.5 g bid orally or azathioprine 1 to 2 mg/kg/day intravenously followed by azathioprine 1 to 2 mg/kg/day orally, in combination with cyclosporine (Neoral<span class="Sup">®</span>) and corticosteroids as maintenance immunosuppressive therapy. The actual median oral dose of azathioprine on study was 1.5 mg/kg/day (range of 0.3 to 3.8 mg/kg/day) initially and 1.26 mg/kg/day (range of 0.3 to 3.8 mg/kg/day) at 12 months. The two primary endpoints were: (1) the proportion of patients who experienced, in the first 6 months posttransplantation, one or more episodes of biopsy-proven and treated rejection or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or retransplantation, and (2) the proportion of patients who experienced graft loss (<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or retransplantation) during the first 12 months posttransplantation. Patients who prematurely discontinued treatment were followed for the occurrence of allograft rejection and for the occurrence of graft loss (<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or retransplantation) for 1 year.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_87b5389f-73ce-485c-ab4a-d20cc4826b0f"></a><a name="section-3.4.1"></a><p></p>
<h3><span class="Bold">Results</span></h3>
<p class="First">In combination with corticosteroids and cyclosporine, CellCept obtained a lower rate of acute rejection at 6 months and a similar rate of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or retransplantation at 1 year compared to azathioprine.</p>
<a name="_Reftable7"></a><table width="100%">
<caption><span>Table 7 Rejection at 6 Months/<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> or Retransplantation at 1 Year</span></caption>
<col width="40%">
<col width="30%">
<col width="30%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"></th>
<th class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">AZA</span><br><span class="Bold"> N = 287</span>
</th>
<th class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">CellCept</span><br><span class="Bold"> N = 278</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Biopsy-proven, treated rejection at 6 months (includes <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or retransplantation)</p></td>
<td class="Botrule Rrule Toprule"><p class="First">137 (47.7%)</p></td>
<td class="Botrule Rrule Toprule"><p class="First">107 (38.5%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> or retransplantation at 1 year</p></td>
<td class="Botrule Rrule"><p class="First">42 (14.6%)</p></td>
<td class="Botrule Rrule"><p class="First">41 (14.7%)</p></td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_a5790b7b-bbfd-4e5e-a3b6-346accb514ed"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_90c054a7-fe38-4fca-b6d7-49a65604b53e"></a><a name="section-4.1"></a><p></p>
<h2>Renal, Cardiac, and Hepatic Transplant</h2>
<p class="First">CellCept is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. CellCept should be used concomitantly with cyclosporine and corticosteroids.</p>
<p>CellCept Intravenous is an alternative dosage form to CellCept capsules, tablets and oral suspension. CellCept Intravenous should be administered within 24 hours following transplantation. CellCept Intravenous can be administered for up to 14 days; patients should be switched to oral CellCept as soon as they can tolerate oral medication.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_e4f8a5e8-c56e-49e7-b99d-bfa5e8971397"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> to CellCept have been observed; therefore, CellCept is contraindicated in patients with a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to mycophenolate mofetil, mycophenolic acid or any component of the drug product. CellCept Intravenous is contraindicated in patients who are allergic to Polysorbate 80 (TWEEN).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">(see <a href="#BOX">boxed WARNING</a>) </span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="WarnET"></a><a name="section-6.1"></a><p></p>
<h2>Embryofetal Toxicity</h2>
<p class="First">Mycophenolate mofetil (MMF) can cause fetal harm when administered to a pregnant female. Use of MMF during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations, especially external ear and other facial abnormalities including <span class="product-label-link" type="condition" conceptid="134144" conceptname="Cleft palate with cleft lip">cleft lip and palate</span>, and anomalies of the distal limbs, heart, esophagus, and kidney (see <span class="Bold"><a href="#PrePreg">PRECAUTIONS: Pregnancy</a>).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_16df3319-21d1-46f7-a210-d71038113ed4"></a><a name="section-6.2"></a><p></p>
<h2>Pregnancy Exposure Prevention and Planning</h2>
<p class="First">Females of reproductive potential must be made aware of the increased risk of first trimester pregnancy loss and congenital malformations and must be counseled regarding pregnancy prevention and planning.  For recommended pregnancy testing and contraception methods (see <span class="Bold"><a href="#PrePlan">PRECAUTIONS: Pregnancy Exposure Prevention and Planning</a>).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="WarnLM"></a><a name="section-6.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> and Malignancy</h2>
<p class="First">Patients receiving immunosuppressive regimens involving combinations of drugs, including CellCept, as part of an immunosuppressive regimen are at increased risk of developing <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> and other malignancies, particularly of the skin (see <span class="Bold"><a href="#AR">ADVERSE REACTIONS</a></span>). The risk appears to be related to the intensity and duration of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> rather than to the use of any specific agent. </p>
<p>As usual for patients with increased risk for skin cancer, exposure to sunlight and UV light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.</p>
<p>Lymphoproliferative disease or <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> developed in 0.4% to 1% of patients receiving CellCept (2 g or 3 g) with other immunosuppressive agents in controlled clinical trials of renal, cardiac, and hepatic transplant patients (see <span class="Bold"><a href="#AR">ADVERSE REACTIONS</a></span>).</p>
<p>In pediatric patients, no other malignancies besides <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorder</span> (2/148 patients) have been observed (see <span class="Bold"><a href="#AR">ADVERSE REACTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c3f35b8c-a1ac-4afd-852a-c6d1585320b8"></a><a name="section-6.4"></a><p></p>
<h2>Combination with Other Immunosuppressive Agents</h2>
<p class="First">CellCept has been administered in combination with the following agents in clinical trials: antithymocyte globulin (ATGAM<span class="Sup">®</span>), OKT3 (Orthoclone OKT<span class="Sup">®</span> 3), cyclosporine (Sandimmune<span class="Sup">®</span>, Neoral<span class="Sup">®</span>) and corticosteroids. The efficacy and safety of the use of CellCept in combination with other immunosuppressive agents have not been determined.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="WarnInfections"></a><a name="section-6.5"></a><p></p>
<h2>Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Patients receiving immunosuppressants, including CellCept, are at increased risk of developing bacterial, fungal, protozoal and new or reactivated <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. These <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may lead to serious, including fatal outcomes. Because of the danger of oversuppression of the immune system which can increase susceptibility to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, combination immunosuppressant therapy should be used with caution (see <span class="Bold"><a href="#AR">ADVERSE REACTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Latent"></a><a name="section-6.6"></a><p></p>
<h2>New or Reactivated <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral Infections</span></h2>
<p class="First">Polyomavirus associated <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span> (PVAN), JC virus associated <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">progressive multifocal leukoencephalopathy</span> (PML), cytomegalovirus (CMV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, reactivation of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B (HBV) or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C (HCV) have been reported in patients treated with immunosuppressants, including CellCept. Reduction in <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> should be considered for patients who develop evidence of new or reactivated <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span>. Physicians should also consider the risk that reduced <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> represents to the functioning allograft.</p>
<p>PVAN, especially due to BK virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, is associated with serious outcomes, including deteriorating renal function and renal graft loss (see <span class="Bold"><a href="#ARPE">ADVERSE REACTIONS: Postmarketing Experience</a></span>). Patient monitoring may help detect patients at risk for PVAN.</p>
<p>PML, which is sometimes fatal, commonly presents with <span class="product-label-link" type="condition" conceptid="4065756" conceptname="Hemiparesis">hemiparesis</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, cognitive deficiencies, and <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>. Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function (see <span class="Bold"><a href="#ARPE">ADVERSE REACTIONS: Postmarketing Experience</a></span>). In immunosuppressed patients, physicians should consider PML in the differential diagnosis in patients reporting neurological symptoms and consultation with a neurologist should be considered as clinically indicated.</p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="45757222" conceptname="Cytomegalovirus viraemia">CMV viremia</span> and CMV disease is highest among transplant recipients seronegative for CMV at time of transplant who receive a graft from a CMV seropositive donor. Therapeutic approaches to limiting CMV disease exist and should be routinely provided. Patient monitoring may help detect patients at risk for CMV disease.</p>
<p>Viral reactivation has been reported in patients infected with HBV or HCV.  Monitoring infected patients for clinical and laboratory signs of active HBV or HCV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="WarnNeutropenia"></a><a name="section-6.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></h2>
<p class="First">Severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> [absolute neutrophil count (ANC) &lt;0.5 × 10<span class="Sup">3</span>/µL] developed in up to 2.0% of renal, up to 2.8% of cardiac, and up to 3.6% of hepatic transplant patients receiving CellCept 3 g daily (see <span class="Bold"><a href="#AR">ADVERSE REACTIONS</a></span>). Patients receiving CellCept should be monitored for <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (see <span class="Bold"><a href="#PreLT">PRECAUTIONS: Laboratory Tests</a></span>). The development of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> may be related to CellCept itself, concomitant medications, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span>, or some combination of these causes. If <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> develops (ANC &lt;1.3 × 10<span class="Sup">3</span>/µL), dosing with CellCept should be interrupted or the dose reduced, appropriate diagnostic tests performed, and the patient managed appropriately (see <span class="Bold"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span>). <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> has been observed most frequently in the period from 31 to 180 days posttransplant in patients treated for prevention of renal, cardiac, and hepatic rejection.</p>
<p>Patients receiving CellCept should be instructed to report immediately any evidence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, unexpected <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or any other manifestation of <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2db00bcd-f865-4338-8776-9815cf292420"></a><a name="section-6.8"></a><p></p>
<h2>Pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">Red Cell Aplasia</span> (PRCA)</h2>
<p class="First">Cases of pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span> (PRCA) have been reported in patients treated with CellCept in combination with other immunosuppressive agents. The mechanism for mycophenolate mofetil induced PRCA is unknown; the relative contribution of other immunosuppressants and their combinations in an <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> regimen are also unknown. In some cases, PRCA was found to be reversible with dose reduction or cessation of CellCept therapy. In transplant patients, however, reduced <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> may place the graft at risk.</p>
<p>CAUTION: CELLCEPT INTRAVENOUS SOLUTION SHOULD NEVER BE ADMINISTERED BY RAPID OR BOLUS INTRAVENOUS INJECTION.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="Precautions"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="PrePlan"></a><a name="section-7.1"></a><p></p>
<h2>Pregnancy Exposure Prevention and Planning</h2>
<p class="First">Females of reproductive potential must be made aware of the increased risk of first trimester pregnancy loss and congenital malformations and must be counseled regarding pregnancy prevention and planning.</p>
<p>Females of reproductive potential include girls who have entered puberty and all women who have a uterus and have not passed through <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>. <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span> is the permanent end of menstruation and fertility. <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span> should be clinically confirmed by a patient's healthcare practitioner. Some commonly used diagnostic criteria include 1) 12 months of spontaneous <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> (not <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> induced by a medical condition or medical therapy) or 2) postsurgical from a bilateral oophorectomy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c43b46a5-4ca5-4fda-9767-8b345c290054"></a><a name="section-7.2"></a><p></p>
<h2>Pregnancy Testing</h2>
<p class="First">To prevent unplanned exposure during pregnancy, females of reproductive potential should have a serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL immediately before starting CellCept. Another pregnancy test with the same sensitivity should be done 8 to 10 days later. Repeat pregnancy tests should be performed during routine follow-up visits. Results of all pregnancy tests should be discussed with the patient.</p>
<p>In the event of a <span class="product-label-link" type="condition" conceptid="4094910" conceptname="Pregnancy test positive">positive pregnancy test</span>, females should be counseled with regard to whether the maternal benefits of mycophenolate treatment may outweigh the risks to the fetus in certain situations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f2aaa43a-4004-4969-bd7d-db01dbebfa9f"></a><a name="section-7.3"></a><p></p>
<h2>Contraception</h2>
<p class="First">Females of reproductive potential taking CellCept must receive contraceptive counseling and use acceptable contraception (see <span class="Bold"><a href="#_Reftable8">Table 8</a></span> for acceptable contraception methods). Patients must use acceptable birth control during entire CellCept therapy, and for 6 weeks after stopping CellCept, unless the patient chooses abstinence (she chooses to avoid heterosexual intercourse completely).</p>
<p>Patients should be aware that CellCept reduces blood levels of the hormones in the oral contraceptive pill and could theoretically reduce its effectiveness (see <span class="Bold"><a href="#PreIFP">PRECAUTIONS: Information for Patients </a></span>and<span class="Bold"><a href="#PreDIOC"> PRECAUTIONS: Drug Interactions: Oral Contraceptives</a></span>).</p>
<a name="_Reftable8"></a><table width="100%">
<caption><span>Table 8	Acceptable Contraception Methods for Females of Reproductive Potential</span></caption>
<col width="15%">
<col width="38%">
<col width="10%">
<col width="37%">
<thead><tr class="First Last"><th class="Botrule Toprule" align="left" colspan="4" valign="top"><span class="Bold">Pick from the following birth control options:</span></th></tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule"><p class="First"><span class="Bold">Option 1</span></p></td>
<td class="Rrule Toprule" colspan="3"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Methods to Use Alone</span></p></td>
<td class="Botrule Rrule" colspan="3" valign="bottom"><dl>
<dt>•</dt>
<dd>Intrauterine devices (IUDs)</dd>
<dt>•</dt>
<dd>Tubal sterilization</dd>
<dt>•</dt>
<dd>Patient's partner had a vasectomy</dd>
</dl></td>
</tr>
<tr><td class="Botrule" colspan="4"><p class="First"><span class="Bold">OR</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Option 2</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Hormone Methods</span><br>choose 1</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Barrier Methods</span><br>choose 1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Choose One Hormone Method </span><span class="Italics">AND</span><span class="Bold"> One Barrier Method</span></p></td>
<td class="Botrule Rrule" valign="bottom">
<p class="First"><span class="Bold">Estrogen and Progesterone</span></p>
<dl>
<dt>•</dt>
<dd>Oral Contraceptive Pill</dd>
<dt>•</dt>
<dd>Transdermal patch</dd>
<dt>•</dt>
<dd>Vaginal ring</dd>
</dl>
<p><span class="Bold">Progesterone-only</span></p>
<dl>
<dt>•</dt>
<dd>Injection</dd>
<dt>•</dt>
<dd>Implant</dd>
</dl>
</td>
<td class="Botrule Rrule"><p class="First"><span class="Italics">AND</span></p></td>
<td class="Botrule Rrule"><dl>
<dt>•</dt>
<dd>Diaphragm with spermicide</dd>
<dt>•</dt>
<dd>Cervical cap with spermicide</dd>
<dt>•</dt>
<dd>Contraceptive sponge</dd>
<dt>•</dt>
<dd>Male condom</dd>
<dt>•</dt>
<dd>Female condom</dd>
</dl></td>
</tr>
<tr><td class="Botrule" colspan="4"><p class="First"><span class="Bold">OR</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Option 3</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Barrier Methods</span><br>choose 1</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Barrier Methods</span><br>choose 1</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Choose One Barrier Method from each column </span><span class="Italics">(must choose two methods)</span></p></td>
<td class="Botrule Rrule" valign="middle"><dl>
<dt>•</dt>
<dd>Diaphragm with spermicide</dd>
<dt>•</dt>
<dd>Cervical cap with spermicide</dd>
<dt>•</dt>
<dd>Contraceptive sponge</dd>
</dl></td>
<td class="Botrule Rrule"><p class="First"><span class="Italics">AND</span></p></td>
<td class="Botrule Rrule"><dl>
<dt>•</dt>
<dd>Male condom</dd>
<dt>•</dt>
<dd>Female condom</dd>
</dl></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1c184083-c931-49dd-a834-a4231363703d"></a><a name="section-7.4"></a><p></p>
<h2>Pregnancy Planning</h2>
<p class="First">For patients who are considering pregnancy, consider alternative immunosuppressants with less potential for embryofetal toxicity. Risks and benefits of CellCept should be discussed with the patient.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_24af7d34-b253-40d3-8a25-78a5e8ae95ff"></a><a name="section-7.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span> (requiring hospitalization) has been observed in approximately 3% of renal, in 1.7% of cardiac, and in 5.4% of hepatic transplant patients treated with CellCept 3 g daily. In pediatric renal transplant patients, 5/148 cases of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> (requiring hospitalization) were observed.</p>
<p><span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal perforations</span> have rarely been observed. Most patients receiving CellCept were also receiving other drugs known to be associated with these complications. Patients with active <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> were excluded from enrollment in studies with mycophenolate mofetil. Because CellCept has been associated with an increased incidence of digestive system adverse events, including infrequent cases of gastrointestinal tract ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, and perforation, CellCept should be administered with caution in patients with active serious digestive system disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="PreRenal"></a><a name="section-7.6"></a><p></p>
<h2>Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Subjects with severe <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic renal impairment</span> (GFR &lt;25 mL/min/1.73 m<span class="Sup">2</span>) who have received single doses of CellCept showed higher plasma MPA and MPAG AUCs relative to subjects with lesser degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or normal healthy volunteers. No data are available on the safety of long-term exposure to these levels of MPAG. Doses of CellCept greater than 1 g administered twice a day to renal transplant patients should be avoided and they should be carefully observed (see <span class="Bold"><a href="#Pharmacokinetics">CLINICAL PHARMACOLOGY: Pharmacokinetics</a></span> and <span class="Bold"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>No data are available for cardiac or hepatic transplant patients with severe <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic renal impairment</span>. CellCept may be used for cardiac or hepatic transplant patients with severe <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic renal impairment</span> if the potential benefits outweigh the potential risks.</p>
<p>In patients with delayed renal graft function posttransplant, mean MPA AUC(0-12h) was comparable, but MPAG AUC(0-12h) was 2-fold to 3-fold higher, compared to that seen in posttransplant patients without delayed renal graft function. In the three controlled studies of prevention of renal rejection, there were 298 of 1483 patients (20%) with delayed graft function. Although patients with delayed graft function have a higher incidence of certain adverse events (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>) than patients without delayed graft function, these events were not more frequent in patients receiving CellCept than azathioprine or placebo. No dose adjustment is recommended for these patients; however, they should be carefully observed (see <span class="Bold"><a href="#Pharmacokinetics">CLINICAL PHARMACOLOGY: Pharmacokinetics</a></span> and <span class="Bold"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_422bb8a2-f8da-41fe-b991-c1bdae47274c"></a><a name="section-7.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in Cardiac Transplant Patients</h2>
<p class="First">In cardiac transplant patients, the overall incidence of <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> was approximately 10% higher in patients treated with CellCept than in those receiving azathioprine therapy, but this difference was not associated with excess mortality due to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>/<span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> among patients treated with CellCept (see <span class="Bold"><a href="#AR">ADVERSE REACTIONS</a></span>).</p>
<p>There were more herpes virus (H. simplex, H. zoster, and cytomegalovirus) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in cardiac transplant patients treated with CellCept compared to those treated with azathioprine (see <span class="Bold"><a href="#AR">ADVERSE REACTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2c168cfc-b5df-4e93-8b9c-8ae725e0b0c5"></a><a name="section-7.8"></a><p></p>
<h2>Concomitant Medications</h2>
<p class="First">It is recommended that CellCept not be administered concomitantly with azathioprine because both have the potential to cause bone marrow suppression and such concomitant administration has not been studied clinically.</p>
<p>In view of the significant reduction in the AUC of MPA by cholestyramine, caution should be used in the concomitant administration of CellCept with drugs that interfere with enterohepatic recirculation because of the potential to reduce the efficacy of CellCept (see <span class="Bold"><a href="#PreDI">PRECAUTIONS: Drug Interactions</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_960285d8-0e41-4d85-ba85-3840529e402b"></a><a name="section-7.9"></a><p></p>
<h2>Patients with HGPRT Deficiency</h2>
<p class="First">On theoretical grounds, because CellCept is an IMPDH (inosine monophosphate dehydrogenase) inhibitor, it should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="PreImm"></a><a name="section-7.10"></a><p></p>
<h2>Immunizations</h2>
<p class="First">During treatment with CellCept, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective (see <span class="Bold"><a href="#PreDILV">PRECAUTIONS: Drug Interactions: Live Vaccines</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_23c53b34-7002-42c0-ad36-f1ab064446a0"></a><a name="section-7.11"></a><p></p>
<h2>Phenylketonurics</h2>
<p class="First">CellCept Oral Suspension contains aspartame, a source of phenylalanine (0.56 mg phenylalanine/mL suspension). Therefore, care should be taken if CellCept Oral Suspension is administered to patients with <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">phenylketonuria</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="PreIFP"></a><a name="section-7.12"></a><p></p>
<h2>Information for Patients</h2>
<p class="First"><span class="Italics"><a href="#MG">See Medication Guide</a></span></p>
<dl>
<dt>•</dt>
<dd>Inform females of reproductive potential that use of CellCept during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations, and advise them as to the appropriate steps to manage these risks, including that they must use acceptable contraception (see <span class="Bold"><a href="#WarnET">WARNINGS: Embryofetal Toxicity</a>, <a href="#PrePlan">PRECAUTIONS: Pregnancy Exposure Prevention and Planning</a>).</span>
</dd>
<dt>•</dt>
<dd>Discuss pregnancy testing, pregnancy prevention and planning with females of reproductive potential. In the event of a <span class="product-label-link" type="condition" conceptid="4094910" conceptname="Pregnancy test positive">positive pregnancy test</span>, females should be counseled with regard to whether the maternal benefits of mycophenolate treatment may outweigh the risks to the fetus in certain situations.</dd>
<dt>•</dt>
<dd>Females of reproductive potential must use acceptable birth control during entire CellCept therapy and for 6 weeks after stopping CellCept, unless the patient chooses to avoid heterosexual intercourse completely (abstinence) (see <span class="Bold"><a href="#_Reftable8">PRECAUTIONS: Pregnancy Exposure Prevention and Planning, Table 8</a>)</span>.</dd>
<dt>•</dt>
<dd>For patients who are considering pregnancy, discuss appropriate alternative immunosuppressants with less potential for embryofetal toxicity. Risks and benefits of CellCept should be discussed with the patient.</dd>
<dt>•</dt>
<dd>Give patients complete dosage instructions and inform them about the increased risk of lymphoproliferative disease and certain other malignancies.</dd>
<dt>•</dt>
<dd>Inform patients that they need repeated appropriate laboratory tests while they are taking CellCept.</dd>
<dt>•</dt>
<dd>Advise patients that they should not breastfeed during CellCept therapy.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="PreLT"></a><a name="section-7.13"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Complete blood counts should be performed weekly during the first month, twice monthly for the second and third months of treatment, then monthly through the first year (see <span class="Bold"><a href="#Warnings">WARNINGS</a>, <a href="#AR">ADVERSE REACTIONS</a></span> and<span class="Bold"><a href="#DA"> DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="PreDI"></a><a name="section-7.14"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Drug interaction studies with mycophenolate mofetil have been conducted with acyclovir, antacids, cholestyramine, cyclosporine, ganciclovir, oral contraceptives, sevelamer, trimethoprim/sulfamethoxazole, norfloxacin, and metronidazole. Drug interaction studies have not been conducted with other drugs that may be commonly administered to renal, cardiac or hepatic transplant patients. CellCept has not been administered concomitantly with azathioprine.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0ab52995-7288-4a17-8dbf-d90480999d36"></a><a name="section-7.14.1"></a><p></p>
<h3><span class="Bold">Acyclovir</span></h3>
<p class="First">Coadministration of mycophenolate mofetil (1 g) and acyclovir (800 mg) to 12 healthy volunteers resulted in no significant change in MPA AUC and C<span class="Sub">max</span>. However, MPAG and acyclovir plasma AUCs were increased 10.6% and 21.9%, respectively. Because MPAG plasma concentrations are increased in the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, as are acyclovir concentrations, the potential exists for mycophenolate and acyclovir or its prodrug (eg, valacyclovir) to compete for tubular secretion, further increasing the concentrations of both drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_eaece085-2176-434c-a073-f3f6d7a9e712"></a><a name="section-7.14.2"></a><p></p>
<h3><span class="Bold">Antacids With Magnesium and Aluminum Hydroxides</span></h3>
<p class="First">Absorption of a single dose of mycophenolate mofetil (2 g) was decreased when administered to ten <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> patients also taking Maalox<span class="Sup">®</span> TC (10 mL qid). The C<span class="Sub">max</span> and AUC(0-24h) for MPA were 33% and 17% lower, respectively, than when mycophenolate mofetil was administered alone under fasting conditions. CellCept may be administered to patients who are also taking antacids containing magnesium and aluminum hydroxides; however, it is recommended that CellCept and the antacid not be administered simultaneously.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_27a94253-4ac8-4daa-a8d2-9182ef583056"></a><a name="section-7.14.3"></a><p></p>
<h3><span class="Bold">Proton Pump Inhibitors (PPIs)</span></h3>
<p class="First">Coadministration of PPIs (e.g., lansoprazole, pantoprazole) in single doses to healthy volunteers and multiple doses to transplant patients receiving CellCept has been reported to reduce the exposure to mycophenolic acid (MPA). An approximate reduction of 30 to 70% in the C<span class="Sub">max</span> and 25% to 35% in the AUC of MPA has been observed, possibly due to a decrease in MPA solubility at an increased gastric pH. The clinical impact of reduced MPA exposure on organ rejection has not been established in transplant patients receiving PPIs and CellCept. Because clinical relevance has not been established, PPIs should be used with caution when coadministered to transplant patients being treated with CellCept.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ae157f7c-c5c2-4a70-8ebe-769239cd8e02"></a><a name="section-7.14.4"></a><p></p>
<h3><span class="Bold">Cholestyramine</span></h3>
<p class="First">Following single-dose administration of 1.5 g mycophenolate mofetil to 12 healthy volunteers pretreated with 4 g tid of cholestyramine for 4 days, MPA AUC decreased approximately 40%. This decrease is consistent with interruption of enterohepatic recirculation which may be due to binding of recirculating MPAG with cholestyramine in the intestine. Some degree of enterohepatic recirculation is also anticipated following intravenous administration of CellCept. Therefore, CellCept is not recommended to be given with cholestyramine or other agents that may interfere with enterohepatic recirculation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_793b8197-8cc2-4439-bd11-a0799d2d6f9a"></a><a name="section-7.14.5"></a><p></p>
<h3><span class="Bold">Cyclosporine</span></h3>
<p class="First">Cyclosporine (Sandimmune<span class="Sup">®</span>) pharmacokinetics (at doses of 275 to 415 mg/day) were unaffected by single and multiple doses of 1.5 g bid of mycophenolate mofetil in 10 stable renal transplant patients. The mean (±SD) AUC(0-12h) and C<span class="Sub">max</span> of cyclosporine after 14 days of multiple doses of mycophenolate mofetil were 3290 (±822) ng∙h/mL and 753 (±161) ng/mL, respectively, compared to 3245 (±1088) ng∙h/mL and 700 (±246) ng/mL, respectively, 1 week before administration of mycophenolate mofetil. </p>
<p>In renal transplant patients, mean MPA exposure (AUC<span class="Sub">0-12h</span>) was approximately 30-50% greater when mycophenolate mofetil is administered without cyclosporine compared with when mycophenolate mofetil is coadministered with cyclosporine. This interaction is due to cyclosporine inhibition of multidrug-resistance-associated protein 2 (MRP-2) transporter in the biliary tract, thereby preventing the excretion of MPAG into the bile that would lead to enterohepatic recirculation of MPA. This information should be taken into consideration when MMF is used without cyclosporine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_52a5d7ee-cb5b-4858-8666-45a1099cf59d"></a><a name="section-7.14.6"></a><p></p>
<h3><span class="Bold">Ganciclovir</span></h3>
<p class="First">Following single-dose administration to 12 stable renal transplant patients, no <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> was observed between mycophenolate mofetil (1.5 g) and intravenous ganciclovir (5 mg/kg). Mean (±SD) ganciclovir AUC and C<span class="Sub">max</span> (n=10) were 54.3 (±19.0) µg∙h/mL and 11.5 (±1.8) µg/mL, respectively, after coadministration of the two drugs, compared to 51.0 (±17.0) µg∙h/mL and 10.6 (±2.0) µg/mL, respectively, after administration of intravenous ganciclovir alone. The mean (±SD) AUC and C<span class="Sub">max</span> of MPA (n=12) after coadministration were 80.9 (±21.6) µg∙h/mL and 27.8 (±13.9) µg/mL, respectively, compared to values of 80.3 (±16.4) µg∙h/mL and 30.9 (±11.2) µg/mL, respectively, after administration of mycophenolate mofetil alone. Because MPAG plasma concentrations are increased in the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, as are ganciclovir concentrations, the two drugs will compete for tubular secretion and thus further increases in concentrations of both drugs may occur. In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> in which MMF and ganciclovir or its prodrug (eg, valganciclovir) are coadministered, patients should be monitored carefully.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="PreDIOC"></a><a name="section-7.14.7"></a><p></p>
<h3><span class="Bold">Oral Contraceptives</span></h3>
<p class="First">A study of coadministration of CellCept (1 g bid) and combined oral contraceptives containing ethinylestradiol (0.02 mg to 0.04 mg) and levonorgestrel (0.05 mg to 0.20 mg), desogestrel (0.15 mg) or gestodene (0.05 mg to 0.10 mg) was conducted in 18 women with <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> over 3 consecutive menstrual cycles. Mean AUC(0-24h) was similar for ethinylestradiol and 3-keto desogestrel; however, mean levonorgestrel AUC(0-24h) significantly decreased by about 15%. There was large inter-patient variability (%CV in the range of 60% to 70%) in the data, especially for ethinylestradiol. Mean serum levels of LH, FSH and progesterone were not significantly affected. CellCept may not have any influence on the ovulation-suppressing action of the studied oral contraceptives. It is recommended to coadminister CellCept with hormonal contraceptives (eg, birth control pill, transdermal patch, vaginal ring, injection, and implant) with caution and additional barrier contraceptive methods must be used (see <span class="Bold"><a href="#PrePlan">PRECAUTIONS: Pregnancy Exposure Prevention and Planning</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2f53a864-b071-4361-b15f-105665d7b7d1"></a><a name="section-7.14.8"></a><p></p>
<h3><span class="Bold">Sevelamer</span></h3>
<p class="First">Concomitant administration of sevelamer and mycophenolate mofetil in adult and pediatric patients decreased the mean MPA C<span class="Sub">max</span> and AUC<span class="Sub">0-12h</span> by 36% and 26% respectively. This data suggest that sevelamer and other calcium free phosphate binders should not be administered simultaneously with CellCept. Alternatively, it is recommended that sevelamer and other calcium free phosphate binders preferentially could be given 2 hours after CellCept intake to minimize the impact on the absorption of MPA. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_72d72baf-a047-49c2-9cd5-7ca2930a0364"></a><a name="section-7.14.9"></a><p></p>
<h3><span class="Bold">Trimethoprim/sulfamethoxazole</span></h3>
<p class="First">Following single-dose administration of mycophenolate mofetil (1.5 g) to 12 healthy male volunteers on day 8 of a 10 day course of trimethoprim 160 mg/sulfamethoxazole 800 mg administered bid, no effect on the bioavailability of MPA was observed. The mean (±SD) AUC and C<span class="Sub">max</span> of MPA after concomitant administration were 75.2 (±19.8) µg∙h/mL and 34.0 (±6.6) µg/mL, respectively, compared to 79.2 (±27.9) µg∙h/mL and 34.2 (±10.7) µg/mL, respectively, after administration of mycophenolate mofetil alone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1057937c-2ab0-4f29-bbaf-9750ad5cfe78"></a><a name="section-7.14.10"></a><p></p>
<h3><span class="Bold">Norfloxacin and Metronidazole</span></h3>
<p class="First">Following single-dose administration of mycophenolate mofetil (1 g) to 11 healthy volunteers on day 4 of a 5 day course of a combination of norfloxacin and metronidazole, the mean MPA AUC<span class="Sub">0-48h</span> was significantly reduced by 33% compared to the administration of mycophenolate mofetil alone (p&lt;0.05). Therefore, CellCept is not recommended to be given with the combination of norfloxacin and metronidazole. There was no significant effect on mean MPA AUC<span class="Sub">0-48h</span> when mycophenolate mofetil was concomitantly administered with norfloxacin or metronidazole separately. The mean (±SD) MPA AUC<span class="Sub">0-48h</span> after coadministration of mycophenolate mofetil with norfloxacin or metronidazole separately was 48.3 (±24) µg∙h/mL and 42.7 (±23) µg∙h/mL, respectively, compared with 56.2 (±24) µg∙h/mL after administration of mycophenolate mofetil alone. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2bd1e842-507d-40cc-bc89-e55eb360ae3a"></a><a name="section-7.14.11"></a><p></p>
<h3><span class="Bold">Ciprofloxacin and Amoxicillin plus Clavulanic Acid</span></h3>
<p class="First">A total of 64 CellCept-treated renal transplant recipients received either oral ciprofloxacin 500 mg bid or amoxicillin plus clavulanic acid 375 mg tid for 7 or at least 14 days. Approximately 50% reductions in median trough MPA concentrations (pre-dose) from baseline (CellCept alone) were observed in 3 days following commencement of oral ciprofloxacin or amoxicillin plus clavulanic acid. These reductions in trough MPA concentrations tended to diminish within 14 days of antibiotic therapy and ceased within 3 days after discontinuation of antibiotics. The postulated mechanism for this interaction is an antibiotic-induced reduction in glucuronidase-possessing enteric organisms leading to a decrease in enterohepatic recirculation of MPA. The change in trough level may not accurately represent changes in overall MPA exposure; therefore, clinical relevance of these observations is unclear.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_17e9ccaf-22ee-44df-9ac9-d100f63d72e7"></a><a name="section-7.14.12"></a><p></p>
<h3><span class="Bold">Rifampin</span></h3>
<p class="First">In a single heart-lung transplant patient, after correction for dose, a 67% decrease in MPA exposure (AUC<span class="Sub">0-12h</span>) has been observed with concomitant administration of mycophenolate mofetil and rifampin. Therefore, CellCept is not recommended to be given with rifampin concomitantly unless the benefit outweighs the risk.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6cd50673-7dec-4185-a7d5-726200d91dcc"></a><a name="section-7.14.13"></a><p></p>
<h3><span class="Bold">Other Interactions</span></h3>
<p class="First">The measured value for renal clearance of MPAG indicates removal occurs by renal tubular secretion as well as glomerular filtration. Consistent with this, coadministration of probenecid, a known inhibitor of tubular secretion, with mycophenolate mofetil in monkeys results in a 3-fold increase in plasma MPAG AUC and a 2-fold increase in plasma MPA AUC. Thus, other drugs known to undergo renal tubular secretion may compete with MPAG and thereby raise plasma concentrations of MPAG or the other drug undergoing tubular secretion.</p>
<p>Drugs that alter the gastrointestinal flora may interact with mycophenolate mofetil by disrupting enterohepatic recirculation. Interference of MPAG hydrolysis may lead to less MPA available for absorption.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="PreDILV"></a><a name="section-7.14.14"></a><p></p>
<h3><span class="Bold">Live Vaccines</span></h3>
<p class="First">During treatment with CellCept, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective (see <span class="Bold"><a href="#PreImm">PRECAUTIONS: Immunizations</a></span>). <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span> vaccination may be of value. Prescribers should refer to national guidelines for <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span> vaccination.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_b6d30cee-3069-4295-808d-ab5ac8bc9fc2"></a><a name="section-7.15"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a 104-week oral carcinogenicity study in mice, mycophenolate mofetil in daily doses up to 180 mg/kg was not tumorigenic. The highest dose tested was 0.5 times the recommended clinical dose (2 g/day) in renal transplant patients and 0.3 times the recommended clinical dose (3 g/day) in cardiac transplant patients when corrected for differences in body surface area (BSA). In a 104-week oral carcinogenicity study in rats, mycophenolate mofetil in daily doses up to 15 mg/kg was not tumorigenic. The highest dose was 0.08 times the recommended clinical dose in renal transplant patients and 0.05 times the recommended clinical dose in cardiac transplant patients when corrected for BSA. While these animal doses were lower than those given to patients, they were maximal in those species and were considered adequate to evaluate the potential for human risk (see <span class="Bold"><a href="#Warnings">WARNINGS</a></span>).</p>
<p>The genotoxic potential of mycophenolate mofetil was determined in five assays. Mycophenolate mofetil was genotoxic in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>/thymidine kinase assay and the in vivo mouse micronucleus assay. Mycophenolate mofetil was not genotoxic in the bacterial mutation assay, the yeast mitotic gene conversion assay or the Chinese hamster ovary cell chromosomal aberration assay.</p>
<p>Mycophenolate mofetil had no effect on fertility of male rats at oral doses up to 20 mg/kg/day. This dose represents 0.1 times the recommended clinical dose in renal transplant patients and 0.07 times the recommended clinical dose in cardiac transplant patients when corrected for BSA. In a female fertility and reproduction study conducted in rats, oral doses of 4.5 mg/kg/day caused malformations (principally of the head and eyes) in the first generation offspring in the absence of maternal toxicity. This dose was 0.02 times the recommended clinical dose in renal transplant patients and 0.01 times the recommended clinical dose in cardiac transplant patients when corrected for BSA. No effects on fertility or reproductive parameters were evident in the dams or in the subsequent generation.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="PrePreg"></a><a name="section-7.16"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="ID_43c6e419-2590-4063-af17-b86ab5a7be40"></a><a name="section-7.16.1"></a><p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a7ae8efa-ecab-4b85-8bac-a78ce063303b"></a><a name="section-7.16.1.1"></a><p></p>
<h4><span class="Bold">Pregnancy Category D</span></h4>
<p class="First">See <span class="Bold"><a href="#Warnings">WARNINGS</a></span> section.</p>
<p>Use of MMF during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations, especially external ear and other facial abnormalities including <span class="product-label-link" type="condition" conceptid="134144" conceptname="Cleft palate with cleft lip">cleft lip and palate</span>, and anomalies of the distal limbs, heart, esophagus, and kidney.  In animal studies, congenital malformations and pregnancy loss occurred when pregnant rats and rabbits received mycophenolic acid at dose multiples similar to and less than clinical doses.  If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
<p>Risks and benefits of CellCept should be discussed with the patient. When appropriate, consider alternative immunosuppressants with less potential for embryofetal toxicity. In certain situations, the patient and her healthcare practitioner may decide that the maternal benefits outweigh the risks to the fetus. For those females using CellCept at any time during pregnancy and those becoming pregnant within 6 weeks of discontinuing therapy, the healthcare practitioner should report the pregnancy to the Mycophenolate Pregnancy Registry (1-800-617-8191). The healthcare practitioner should strongly encourage the patient to enroll in the pregnancy registry. The information provided to the registry will help the healthcare community better understand the effects of mycophenolate in pregnancy.</p>
<p>In the National Transplantation Pregnancy Registry (NTPR), there were data on 33 MMF-exposed pregnancies in 24 transplant patients; there were 15 <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortions</span> (45%) and 18 live-born infants. Four of these 18 infants had structural malformations (22%). In postmarketing data (collected 1995-2007) on 77 females exposed to systemic MMF during pregnancy, 25 had <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortions</span> and 14 had a malformed infant or fetus. Six of 14 malformed offspring had ear abnormalities. Because these postmarketing data are reported voluntarily, it is not always possible to reliably estimate the frequency of particular adverse outcomes. These malformations are similar to findings in animal reproductive toxicology studies. For comparison, the background rate for congenital anomalies in the United States is about 3%, and NTPR data show a rate of 4-5% among babies born to organ transplant patients using other immunosuppressive drugs.</p>
<p>In animal reproductive toxicology studies, there were increased rates of fetal resorptions and malformations in the absence of maternal toxicity. Female rats and rabbits received mycophenolate mofetil (MMF) doses equivalent to 0.02 to 0.9 times the recommended human dose for renal and cardiac transplant patients, based on body surface area conversions. In rat offspring, malformations included <span class="product-label-link" type="condition" conceptid="434143" conceptname="Anophthalmos">anophthalmia</span>, agnathia, and <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephaly</span>. In rabbit offspring, malformations included <span class="product-label-link" type="condition" conceptid="4302306" conceptname="Ectopia cordis">ectopia cordis</span>, ectopic kidneys, <span class="product-label-link" type="condition" conceptid="201061" conceptname="Diaphragmatic hernia">diaphragmatic hernia</span>, and <span class="product-label-link" type="condition" conceptid="4245842" conceptname="Umbilical hernia">umbilical hernia</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_1e8ac0ef-2ed6-40d4-bdcc-bdf048deaf95"></a><a name="section-7.17"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Studies in rats treated with mycophenolate mofetil have shown mycophenolic acid to be excreted in milk. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from mycophenolate mofetil, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_dd74e44b-f672-4c31-a41d-0af394b689c3"></a><a name="section-7.18"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Based on pharmacokinetic and safety data in pediatric patients after renal transplantation, the recommended dose of CellCept oral suspension is 600 mg/m<span class="Sup">2</span> bid (up to a maximum of 1 g bid). Also see <span class="Bold"><a href="#CP">CLINICAL PHARMACOLOGY</a>, <a href="#CS">CLINICAL STUDIES</a>, <a href="#AR">ADVERSE REACTIONS</a>, </span>and<span class="Bold"><a href="#DA"> DOSAGE AND ADMINISTRATION</a></span>.</p>
<p>Safety and effectiveness in pediatric patients receiving allogeneic cardiac or hepatic transplants have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="PreGeriatric"></a><a name="section-7.19"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of CellCept did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant or other drug therapy. Elderly patients may be at an increased risk of adverse reactions compared with younger individuals (see <span class="Bold"><a href="#AR">ADVERSE REACTIONS</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AR"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The principal adverse reactions associated with the administration of CellCept include <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and there is evidence of a higher frequency of certain types of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> eg, <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infection</span> (see <span class="Bold"><a href="#WarnInfections">WARNINGS: Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>  </a></span> and <span class="Bold"><a href="#Latent"> WARNINGS: New or Reactivated <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral Infections</span></a></span>). The adverse event profile associated with the administration of CellCept Intravenous has been shown to be similar to that observed after administration of oral dosage forms of CellCept.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ef6ef93a-b6d6-474a-b441-3f96a1e373b1"></a><a name="section-8.1"></a><p></p>
<h2>CellCept Oral</h2>
<p class="First">The incidence of adverse events for CellCept was determined in randomized, comparative, double-blind trials in prevention of rejection in renal (2 active, 1 placebo-controlled trials), cardiac (1 active-controlled trial), and hepatic (1 active-controlled trial) transplant patients.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e634e848-d21b-4904-a72a-cc0cea345601"></a><a name="section-8.1.1"></a><p></p>
<h3><span class="Bold">Geriatrics</span></h3>
<p class="First">Elderly patients (≥65 years), particularly those who are receiving CellCept as part of a combination immunosuppressive regimen, may be at increased risk of certain <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (including cytomegalovirus [CMV] tissue invasive disease) and possibly <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, compared to younger individuals (see <span class="Bold"><a href="#Precautions">PRECAUTIONS</a></span>).</p>
<p>Safety data are summarized below for all active-controlled trials in renal (2 trials), cardiac (1 trial), and hepatic (1 trial) transplant patients. Approximately 53% of the renal patients, 65% of the cardiac patients, and 48% of the hepatic patients have been treated for more than 1 year. Adverse events reported in ≥20% of patients in the CellCept treatment groups are presented below.</p>
<a name="_Reftable9"></a><table width="100%">
<caption><span>Table 9 Adverse Events in Controlled Studies in Prevention of Renal, Cardiac or Hepatic Allograft Rejection (Reported in ≥20% of Patients in the CellCept Group)</span></caption>
<col width="18%">
<col width="10%">
<col width="10%">
<col width="14%">
<col width="10%">
<col width="14%">
<col width="10%">
<col width="14%">
<thead>
<tr class="First">
<th class="Lrule Toprule" align="left" valign="top"></th>
<th class="Botrule Lrule Rrule Toprule" align="left" colspan="3" valign="top"><span class="Bold">Renal Studies</span></th>
<th class="Botrule Rrule Toprule" align="left" colspan="2" valign="top"><span class="Bold">Cardiac Study</span></th>
<th class="Botrule Rrule Toprule" align="left" colspan="2" valign="top"><span class="Bold">Hepatic Study</span></th>
</tr>
<tr>
<th class="Lrule" align="left" valign="top"></th>
<th class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">CellCept</span><br><span class="Bold">  2 g/day</span>
</th>
<th class="Botrule Rrule" align="left" valign="top">
<span class="Bold">CellCept</span><br><span class="Bold">  3 g/day</span>
</th>
<th class="Botrule Rrule" align="left" valign="top">
<span class="Bold">Azathioprine</span><br><span class="Bold">  1 to 2 mg/kg/day or 100 to 150 mg/day</span>
</th>
<th class="Botrule Rrule" align="left" valign="top">
<span class="Bold">CellCept</span><br><span class="Bold">  3 g/day</span>
</th>
<th class="Botrule" align="left" valign="top">
<span class="Bold">Azathioprine</span><br><span class="Bold">  1.5 to 3</span><br><span class="Bold">  mg/kg/day</span>
</th>
<th class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">CellCept</span><br><span class="Bold">  3 g/day</span>
</th>
<th class="Botrule Rrule" align="left" valign="top">
<span class="Bold">Azathioprine</span><br><span class="Bold">  1 to 2 mg/kg/day</span>
</th>
</tr>
<tr>
<th class="Lrule" align="left" valign="top"></th>
<th class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">(n=336)</span></th>
<th class="Botrule Rrule" align="left" valign="top"><span class="Bold">(n=330)</span></th>
<th class="Botrule Rrule" align="left" valign="top"><span class="Bold">(n=326)</span></th>
<th class="Botrule Rrule" align="left" valign="top"><span class="Bold">(n=289)</span></th>
<th class="Botrule" align="left" valign="top"><span class="Bold">(n=289)</span></th>
<th class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">(n=277)</span></th>
<th class="Botrule Rrule" align="left" valign="top"><span class="Bold">(n=287)</span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule" align="left" valign="top"></th>
<th class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">%</span></th>
<th class="Botrule Rrule" align="left" valign="top"><span class="Bold">%</span></th>
<th class="Botrule Rrule" align="left" valign="top"><span class="Bold">%</span></th>
<th class="Botrule Rrule" align="left" valign="top"><span class="Bold">%</span></th>
<th class="Botrule" align="left" valign="top"><span class="Bold">%</span></th>
<th class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">%</span></th>
<th class="Botrule Rrule" align="left" valign="top"><span class="Bold">%</span></th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Toprule"><p class="First"><span class="Bold">Body as a Whole</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule"></td>
<td class="Botrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">33.0</p></td>
<td class="Botrule Rrule"><p class="First">31.2</p></td>
<td class="Botrule Rrule"><p class="First">32.2</p></td>
<td class="Botrule Rrule"><p class="First">75.8</p></td>
<td class="Botrule"><p class="First">74.7</p></td>
<td class="Botrule Lrule Rrule"><p class="First">74.0</p></td>
<td class="Botrule Rrule"><p class="First">77.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">24.7</p></td>
<td class="Botrule Rrule"><p class="First">27.6</p></td>
<td class="Botrule Rrule"><p class="First">23.0</p></td>
<td class="Botrule Rrule"><p class="First">33.9</p></td>
<td class="Botrule"><p class="First">33.2</p></td>
<td class="Botrule Lrule Rrule"><p class="First">62.5</p></td>
<td class="Botrule Rrule"><p class="First">51.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">21.4</p></td>
<td class="Botrule Rrule"><p class="First">23.3</p></td>
<td class="Botrule Rrule"><p class="First">23.3</p></td>
<td class="Botrule Rrule"><p class="First">47.4</p></td>
<td class="Botrule"><p class="First">46.4</p></td>
<td class="Botrule Lrule Rrule"><p class="First">52.3</p></td>
<td class="Botrule Rrule"><p class="First">56.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">21.1</p></td>
<td class="Botrule Rrule"><p class="First">16.1</p></td>
<td class="Botrule Rrule"><p class="First">21.2</p></td>
<td class="Botrule Rrule"><p class="First">54.3</p></td>
<td class="Botrule"><p class="First">51.9</p></td>
<td class="Botrule Lrule Rrule"><p class="First">53.8</p></td>
<td class="Botrule Rrule"><p class="First">49.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">18.2</p></td>
<td class="Botrule Rrule"><p class="First">20.9</p></td>
<td class="Botrule Rrule"><p class="First">19.9</p></td>
<td class="Botrule Rrule"><p class="First">25.6</p></td>
<td class="Botrule"><p class="First">19.4</p></td>
<td class="Botrule Lrule Rrule"><p class="First">27.1</p></td>
<td class="Botrule Rrule"><p class="First">25.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule"><p class="First">27.4</p></td>
<td class="Botrule Rrule"><p class="First">26.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">43.3</p></td>
<td class="Botrule"><p class="First">36.3</p></td>
<td class="Botrule Lrule Rrule"><p class="First">35.4</p></td>
<td class="Botrule Rrule"><p class="First">33.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">26.3</p></td>
<td class="Botrule"><p class="First">26.0</p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">34.6</p></td>
<td class="Botrule"><p class="First">28.4</p></td>
<td class="Botrule Lrule Rrule"><p class="First">46.6</p></td>
<td class="Botrule Rrule"><p class="First">47.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">Ascites</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule"><p class="First">24.2</p></td>
<td class="Botrule Rrule"><p class="First">22.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Hematologic and Lymphatic</span></p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">25.6</p></td>
<td class="Botrule Rrule"><p class="First">25.8</p></td>
<td class="Botrule Rrule"><p class="First">23.6</p></td>
<td class="Botrule Rrule"><p class="First">42.9</p></td>
<td class="Botrule"><p class="First">43.9</p></td>
<td class="Botrule Lrule Rrule"><p class="First">43.0</p></td>
<td class="Botrule Rrule"><p class="First">53.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">23.2</p></td>
<td class="Botrule Rrule"><p class="First">34.5</p></td>
<td class="Botrule Rrule"><p class="First">24.8</p></td>
<td class="Botrule Rrule"><p class="First">30.4</p></td>
<td class="Botrule"><p class="First">39.1</p></td>
<td class="Botrule Lrule Rrule"><p class="First">45.8</p></td>
<td class="Botrule Rrule"><p class="First">39.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">23.5</p></td>
<td class="Botrule"><p class="First">27.0</p></td>
<td class="Botrule Lrule Rrule"><p class="First">38.3</p></td>
<td class="Botrule Rrule"><p class="First">42.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4195171" conceptname="Normocytic hypochromic anemia">Hypochromic anemia</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">24.6</p></td>
<td class="Botrule"><p class="First">23.5</p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">Leukocytosis</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">40.5</p></td>
<td class="Botrule"><p class="First">35.6</p></td>
<td class="Botrule Lrule Rrule"><p class="First">22.4</p></td>
<td class="Botrule Rrule"><p class="First">21.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Urogenital</span></p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">37.2</p></td>
<td class="Botrule Rrule"><p class="First">37.0</p></td>
<td class="Botrule Rrule"><p class="First">33.7</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Kidney function abnormal</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">21.8</p></td>
<td class="Botrule"><p class="First">26.3</p></td>
<td class="Botrule Lrule Rrule"><p class="First">25.6</p></td>
<td class="Botrule Rrule"><p class="First">28.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Cardiovascular</span></p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">32.4</p></td>
<td class="Botrule Rrule"><p class="First">28.2</p></td>
<td class="Botrule Rrule"><p class="First">32.2</p></td>
<td class="Botrule Rrule"><p class="First">77.5</p></td>
<td class="Botrule"><p class="First">72.3</p></td>
<td class="Botrule Lrule Rrule"><p class="First">62.1</p></td>
<td class="Botrule Rrule"><p class="First">59.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">32.5</p></td>
<td class="Botrule"><p class="First">36.0</p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular disorder</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">25.6</p></td>
<td class="Botrule"><p class="First">24.2</p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">20.1</p></td>
<td class="Botrule"><p class="First">18.0</p></td>
<td class="Botrule Lrule Rrule"><p class="First">22.0</p></td>
<td class="Botrule Rrule"><p class="First">15.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Metabolic and Nutritional</span></p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">28.6</p></td>
<td class="Botrule Rrule"><p class="First">27.0</p></td>
<td class="Botrule Rrule"><p class="First">28.2</p></td>
<td class="Botrule Rrule"><p class="First">64.0</p></td>
<td class="Botrule"><p class="First">53.3</p></td>
<td class="Botrule Lrule Rrule"><p class="First">48.4</p></td>
<td class="Botrule Rrule"><p class="First">47.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Hyper-cholesteremia</p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">41.2</p></td>
<td class="Botrule"><p class="First">38.4</p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">26.6</p></td>
<td class="Botrule"><p class="First">25.6</p></td>
<td class="Botrule Lrule Rrule"><p class="First">28.2</p></td>
<td class="Botrule Rrule"><p class="First">28.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">31.8</p></td>
<td class="Botrule"><p class="First">25.6</p></td>
<td class="Botrule Lrule Rrule"><p class="First">37.2</p></td>
<td class="Botrule Rrule"><p class="First">41.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule"><p class="First">22.0</p></td>
<td class="Botrule Rrule"><p class="First">23.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">46.7</p></td>
<td class="Botrule"><p class="First">52.6</p></td>
<td class="Botrule Lrule Rrule"><p class="First">43.7</p></td>
<td class="Botrule Rrule"><p class="First">48.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Creatinine increased</p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">39.4</p></td>
<td class="Botrule"><p class="First">36.0</p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">BUN increased</p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">34.6</p></td>
<td class="Botrule"><p class="First">32.5</p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Lactic dehydrogenase increased</p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">23.2</p></td>
<td class="Botrule"><p class="First">17.0</p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule"><p class="First">39.0</p></td>
<td class="Botrule Rrule"><p class="First">37.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule"><p class="First">30.0</p></td>
<td class="Botrule Rrule"><p class="First">30.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Digestive</span></p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">31.0</p></td>
<td class="Botrule Rrule"><p class="First">36.1</p></td>
<td class="Botrule Rrule"><p class="First">20.9</p></td>
<td class="Botrule Rrule"><p class="First">45.3</p></td>
<td class="Botrule"><p class="First">34.3</p></td>
<td class="Botrule Lrule Rrule"><p class="First">51.3</p></td>
<td class="Botrule Rrule"><p class="First">49.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">22.9</p></td>
<td class="Botrule Rrule"><p class="First">18.5</p></td>
<td class="Botrule Rrule"><p class="First">22.4</p></td>
<td class="Botrule Rrule"><p class="First">41.2</p></td>
<td class="Botrule"><p class="First">37.7</p></td>
<td class="Botrule Lrule Rrule"><p class="First">37.9</p></td>
<td class="Botrule Rrule"><p class="First">38.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">19.9</p></td>
<td class="Botrule Rrule"><p class="First">23.6</p></td>
<td class="Botrule Rrule"><p class="First">24.5</p></td>
<td class="Botrule Rrule"><p class="First">54.0</p></td>
<td class="Botrule"><p class="First">54.3</p></td>
<td class="Botrule Lrule Rrule"><p class="First">54.5</p></td>
<td class="Botrule Rrule"><p class="First">51.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule"><p class="First">22.4</p></td>
<td class="Botrule Rrule"><p class="First">20.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">33.9</p></td>
<td class="Botrule"><p class="First">28.4</p></td>
<td class="Botrule Lrule Rrule"><p class="First">32.9</p></td>
<td class="Botrule Rrule"><p class="First">33.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule"><p class="First">25.3</p></td>
<td class="Botrule Rrule"><p class="First">17.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">Liver function tests abnormal</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule"><p class="First">24.9</p></td>
<td class="Botrule Rrule"><p class="First">19.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Respiratory</span></p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">22.0</p></td>
<td class="Botrule Rrule"><p class="First">23.9</p></td>
<td class="Botrule Rrule"><p class="First">19.6</p></td>
<td class="Botrule Rrule"><p class="First">37.0</p></td>
<td class="Botrule"><p class="First">35.3</p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">36.7</p></td>
<td class="Botrule"><p class="First">36.3</p></td>
<td class="Botrule Lrule Rrule"><p class="First">31.0</p></td>
<td class="Botrule Rrule"><p class="First">30.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough increased</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">31.1</p></td>
<td class="Botrule"><p class="First">25.6</p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">Lung disorder</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">30.1</p></td>
<td class="Botrule"><p class="First">29.1</p></td>
<td class="Botrule Lrule Rrule"><p class="First">22.0</p></td>
<td class="Botrule Rrule"><p class="First">18.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">26.0</p></td>
<td class="Botrule"><p class="First">19.0</p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">Pleural effusion</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule"><p class="First">34.3</p></td>
<td class="Botrule Rrule"><p class="First">35.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Skin and Appendages</span></p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">22.1</p></td>
<td class="Botrule"><p class="First">18.0</p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Nervous System</span></p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">24.2</p></td>
<td class="Botrule"><p class="First">23.9</p></td>
<td class="Botrule Lrule Rrule"><p class="First">33.9</p></td>
<td class="Botrule Rrule"><p class="First">35.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">40.8</p></td>
<td class="Botrule"><p class="First">37.7</p></td>
<td class="Botrule Lrule Rrule"><p class="First">52.3</p></td>
<td class="Botrule Rrule"><p class="First">47.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">28.7</p></td>
<td class="Botrule"><p class="First">27.7</p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">28.4</p></td>
<td class="Botrule"><p class="First">23.9</p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">–</p></td>
<td class="Botrule Rrule"><p class="First">20.8</p></td>
<td class="Botrule"><p class="First">18.0</p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule"><p class="First">–</p></td>
</tr>
</tbody>
</table>
<p>The placebo-controlled renal transplant study generally showed fewer adverse events occurring in ≥20% of patients. In addition, those that occurred were not only qualitatively similar to the azathioprine-controlled renal transplant studies, but also occurred at lower rates, particularly for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infection</span>.</p>
<p>The above data demonstrate that in three controlled trials for prevention of renal rejection, patients receiving 2 g/day of CellCept had an overall better safety profile than did patients receiving 3 g/day of CellCept.</p>
<p>The above data demonstrate that the types of adverse events observed in multicenter controlled trials in renal, cardiac, and hepatic transplant patients are qualitatively similar except for those that are unique to the specific organ involved.</p>
<p><span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span>, which was generally <span class="product-label-link" type="condition" conceptid="45757222" conceptname="Cytomegalovirus viraemia">CMV viremia</span>, was slightly more common in renal transplant patients treated with CellCept compared to patients treated with azathioprine. The incidence of <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> was comparable in CellCept and in azathioprine-treated patients in cardiac and hepatic studies.</p>
<p>In the digestive system, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was increased in renal and cardiac transplant patients receiving CellCept compared to patients receiving azathioprine, but was comparable in hepatic transplant patients treated with CellCept or azathioprine.</p>
<p>Patients receiving CellCept alone or as part of an immunosuppressive regimen are at increased risk of developing <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> and other malignancies, particularly of the skin (see <span class="Bold"><a href="#WarnLM">WARNINGS: <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> and Malignancy</a></span>). The incidence of malignancies among the 1483 patients treated in controlled trials for the prevention of renal allograft rejection who were followed for ≥1 year was similar to the incidence reported in the literature for renal allograft recipients.</p>
<p>Lymphoproliferative disease or <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> developed in 0.4% to 1% of patients receiving CellCept (2 g or 3 g daily) with other immunosuppressive agents in controlled clinical trials of renal, cardiac, and hepatic transplant patients followed for at least 1 year (see <span class="Bold"><a href="#WarnLM">WARNINGS: <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> and Malignancy</a></span>). Non-<span class="product-label-link" type="condition" conceptid="4049499" conceptname="Malignant melanoma">melanoma skin</span> carcinomas occurred in 1.6% to 4.2% of patients, other types of malignancy in 0.7% to 2.1% of patients. Three-year safety data in renal and cardiac transplant patients did not reveal any unexpected changes in incidence of malignancy compared to the 1-year data.</p>
<p>In pediatric patients, no other malignancies besides <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorder</span> (2/148 patients) have been observed.</p>
<p>Severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (ANC &lt;0.5 × 10<span class="Sup">3</span>/µL) developed in up to 2.0% of renal transplant patients, up to 2.8% of cardiac transplant patients and up to 3.6% of hepatic transplant patients receiving CellCept 3 g daily (see <span class="Bold"><a href="#WarnNeutropenia">WARNINGS: <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></a>, <a href="#PreLT">PRECAUTIONS: Laboratory Tests </a></span>and<span class="Bold"><a href="#DA"> DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>All transplant patients are at increased risk of <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. The risk increases with total immunosuppressive load (see <span class="Bold"><a href="#WarnInfections">WARNINGS: Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></span> and <span class="Bold"><a href="#Latent">WARNINGS: New or Reactivated <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral Infections</span></a></span>). <span class="Bold"><a href="#_Reftable10">Table 10</a></span> shows the incidence of <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> that occurred in the renal, cardiac, and hepatic transplant populations in the azathioprine-controlled prevention trials:</p>
<a name="_Reftable10"></a><table width="100%">
<caption><span>Table 10 Viral and <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal Infections</span> in Controlled Studies in Prevention of Renal, Cardiac or Hepatic <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">Transplant Rejection</span></span></caption>
<col width="18%">
<col width="10%">
<col width="10%">
<col width="14%">
<col width="10%">
<col width="14%">
<col width="10%">
<col width="14%">
<thead>
<tr class="First">
<th class="Lrule Toprule" align="left" valign="top"></th>
<th class="Botrule Lrule Rrule Toprule" align="left" colspan="3" valign="top"><span class="Bold">Renal Studies</span></th>
<th class="Botrule Rrule Toprule" align="left" colspan="2" valign="top"><span class="Bold">Cardiac Study</span></th>
<th class="Botrule Rrule Toprule" align="left" colspan="2" valign="top"><span class="Bold">Hepatic Study</span></th>
</tr>
<tr>
<th class="Lrule" align="left" valign="top"></th>
<th class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">CellCept</span><br><span class="Bold"> 2 g/day</span>
</th>
<th class="Botrule Rrule" align="left" valign="top">
<span class="Bold">CellCept </span><br><span class="Bold"> 3 g/day</span>
</th>
<th class="Botrule Rrule" align="left" valign="top">
<span class="Bold">Azathioprine</span><br><span class="Bold"> 1 to 2 mg/kg/day or 100 to 150 mg/day</span>
</th>
<th class="Botrule Rrule" align="left" valign="top">
<span class="Bold">CellCept</span><br><span class="Bold"> 3 g/day</span>
</th>
<th class="Botrule" align="left" valign="top">
<span class="Bold">Azathioprine</span><br><span class="Bold"> 1.5 to 3 mg/kg/day</span>
</th>
<th class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">CellCept</span><br><span class="Bold"> 3 g/day</span>
</th>
<th class="Botrule Rrule" align="left" valign="top">
<span class="Bold">Azathioprine</span><br><span class="Bold"> 1 to 2 mg/kg/day</span>
</th>
</tr>
<tr>
<th class="Lrule" align="left" valign="top"></th>
<th class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">(n=336)</span></th>
<th class="Botrule Rrule" align="left" valign="top"><span class="Bold">(n=330)</span></th>
<th class="Botrule Rrule" align="left" valign="top"><span class="Bold">(n=326)</span></th>
<th class="Botrule Rrule" align="left" valign="top"><span class="Bold">(n=289)</span></th>
<th class="Botrule" align="left" valign="top"><span class="Bold">(n=289)</span></th>
<th class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">(n=277)</span></th>
<th class="Botrule Rrule" align="left" valign="top"><span class="Bold">(n=287)</span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule" align="left" valign="top"></th>
<th class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">%</span></th>
<th class="Botrule Rrule" align="left" valign="top"><span class="Bold">%</span></th>
<th class="Botrule Rrule" align="left" valign="top"><span class="Bold">%</span></th>
<th class="Botrule Rrule" align="left" valign="top"><span class="Bold">%</span></th>
<th class="Botrule" align="left" valign="top"><span class="Bold">%</span></th>
<th class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">%</span></th>
<th class="Botrule Rrule" align="left" valign="top"><span class="Bold">%</span></th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Toprule"><p class="First">Herpes simplex</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">16.7</p></td>
<td class="Botrule Rrule Toprule"><p class="First">20.0</p></td>
<td class="Botrule Rrule Toprule"><p class="First">19.0</p></td>
<td class="Botrule Rrule Toprule"><p class="First">20.8</p></td>
<td class="Botrule Toprule"><p class="First">14.5</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">10.1</p></td>
<td class="Botrule Rrule Toprule"><p class="First">5.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">CMV</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">– <span class="product-label-link" type="condition" conceptid="133327" conceptname="Viremia">Viremia</span>/syndrome</p></td>
<td class="Botrule Lrule Rrule"><p class="First">13.4</p></td>
<td class="Botrule Rrule"><p class="First">12.4</p></td>
<td class="Botrule Rrule"><p class="First">13.8</p></td>
<td class="Botrule Rrule"><p class="First">12.1</p></td>
<td class="Botrule"><p class="First">10.0</p></td>
<td class="Botrule Lrule Rrule"><p class="First">14.1</p></td>
<td class="Botrule Rrule"><p class="First">12.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">– Tissue invasive disease</p></td>
<td class="Botrule Lrule Rrule"><p class="First">8.3</p></td>
<td class="Botrule Rrule"><p class="First">11.5</p></td>
<td class="Botrule Rrule"><p class="First">6.1</p></td>
<td class="Botrule Rrule"><p class="First">11.4</p></td>
<td class="Botrule"><p class="First">8.7</p></td>
<td class="Botrule Lrule Rrule"><p class="First">5.8</p></td>
<td class="Botrule Rrule"><p class="First">8.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes zoster</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">6.0</p></td>
<td class="Botrule Rrule"><p class="First">7.6</p></td>
<td class="Botrule Rrule"><p class="First">5.8</p></td>
<td class="Botrule Rrule"><p class="First">10.7</p></td>
<td class="Botrule"><p class="First">5.9</p></td>
<td class="Botrule Lrule Rrule"><p class="First">4.3</p></td>
<td class="Botrule Rrule"><p class="First">4.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">– Cutaneous disease</p></td>
<td class="Botrule Lrule Rrule"><p class="First">6.0</p></td>
<td class="Botrule Rrule"><p class="First">7.3</p></td>
<td class="Botrule Rrule"><p class="First">5.5</p></td>
<td class="Botrule Rrule"><p class="First">10.0</p></td>
<td class="Botrule"><p class="First">5.5</p></td>
<td class="Botrule Lrule Rrule"><p class="First">4.3</p></td>
<td class="Botrule Rrule"><p class="First">4.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First">17.0</p></td>
<td class="Botrule Rrule"><p class="First">17.3</p></td>
<td class="Botrule Rrule"><p class="First">18.1</p></td>
<td class="Botrule Rrule"><p class="First">18.7</p></td>
<td class="Botrule"><p class="First">17.6</p></td>
<td class="Botrule Lrule Rrule"><p class="First">22.4</p></td>
<td class="Botrule Rrule"><p class="First">24.4</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">– Mucocutaneous</p></td>
<td class="Botrule Lrule Rrule"><p class="First">15.5</p></td>
<td class="Botrule Rrule"><p class="First">16.4</p></td>
<td class="Botrule Rrule"><p class="First">15.3</p></td>
<td class="Botrule Rrule"><p class="First">18.0</p></td>
<td class="Botrule"><p class="First">17.3</p></td>
<td class="Botrule Lrule Rrule"><p class="First">18.4</p></td>
<td class="Botrule Rrule"><p class="First">17.4</p></td>
</tr>
</tbody>
</table>
<p>The following other <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> occurred with an incidence of less than 4% in CellCept patients in the above azathioprine-controlled studies: <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes zoster</span>, visceral disease; <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="4202922" conceptname="Fungemia">fungemia</span>/disseminated disease, tissue invasive disease; <span class="product-label-link" type="condition" conceptid="440035" conceptname="Cryptococcosis">Cryptococcosis</span>; Aspergillus/Mucor; Pneumocystis carinii.</p>
<p>In the placebo-controlled renal transplant study, the same pattern of <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infection</span> was observed compared to the azathioprine-controlled renal studies, with a notably lower incidence of the following: Herpes simplex and CMV tissue-invasive disease. </p>
<p>In patients receiving CellCept (2 g or 3 g) in controlled studies for prevention of renal, cardiac or hepatic rejection, fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>/<span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> occurred in approximately 2% of renal and cardiac patients and in 5% of hepatic patients (see <span class="Bold"><a href="#WarnInfections">WARNINGS: Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></span>). </p>
<p>In cardiac transplant patients, the overall incidence of <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> was approximately 10% higher in patients treated with CellCept than in those receiving azathioprine, but this difference was not associated with excess mortality due to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>/<span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> among patients treated with CellCept.</p>
<p>The following adverse events were reported with 3% to &lt;20% incidence in renal, cardiac, and hepatic transplant patients treated with CellCept, in combination with cyclosporine and corticosteroids.</p>
<a name="_Reftable11"></a><table width="100%">
<caption><span>Table 11 Adverse Events Reported in 3% to &lt;20% of Patients Treated With CellCept in Combination With Cyclosporine and Corticosteroids</span></caption>
<col width="30%">
<col width="70%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Body  System</span></th>
<th class="Botrule Rrule Toprule" align="left" valign="top"></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Body as a Whole</p></td>
<td class="Botrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdomen enlarged</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">accidental injury</span>, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> occurring with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="199860" conceptname="Hernia of abdominal cavity">hernia</span>, lab test abnormal, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>, <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span>, <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Hematologic and Lymphatic</p></td>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorder</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechia</span>, <span class="product-label-link" type="condition" conceptid="435790" conceptname="Secondary polycythemia">polycythemia</span>, <span class="product-label-link" type="condition" conceptid="4260197" conceptname="Prothrombin time increased">prothrombin time increased</span>, thromboplastin time increased</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Urogenital</p></td>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute kidney failure</span>, <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="433811" conceptname="Hydronephrosis">hydronephrosis</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>, <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">kidney tubular necrosis</span>, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="196734" conceptname="Disorder of prostate">prostatic disorder</span>, <span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">pyelonephritis</span>, <span class="product-label-link" type="condition" conceptid="4230799" conceptname="Edema of scrotum">scrotal edema</span>, <span class="product-label-link" type="condition" conceptid="4298419" conceptname="Cloudy urine">urine abnormality</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="197331" conceptname="Disorder of urinary tract">urinary tract disorder</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Cardiovascular</p></td>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">cardiovascular disorder</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, extrasystole, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">heart arrest</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span>, <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disorder</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>, <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="441872" conceptname="Supraventricular premature beats">supraventricular extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>, <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, ventricular extrasystole, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4289004" conceptname="Increased venous pressure">venous pressure increased</span></p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Metabolic and Nutritional</p></td>
<td class="Rrule"><p class="First">abnormal healing, <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, alkaline phosphatase increased, <span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">alkalosis</span>, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">bilirubinemia</span>, creatinine increased, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4171925" conceptname="Gamma-glutamyl transferase raised">gamma glutamyl transpeptidase increased</span>, <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesteremia</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipemia</span>, <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">hypochloremia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span>, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, lactic dehydrogenase increased, <span class="product-label-link" type="condition" conceptid="4048509" conceptname="Respiratory acidosis">respiratory acidosis</span>, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> increased, SGPT increased, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Digestive</p></td>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="195856" conceptname="Cholangitis">cholangitis</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorder</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="193133" conceptname="Gastrointestinal candidiasis">gastrointestinal moniliasis</span>, <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">gingivitis</span>, gum <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span>, <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">liver function tests abnormal</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulceration</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral moniliasis</span>, <span class="product-label-link" type="condition" conceptid="79069" conceptname="Disorder of rectum">rectal disorder</span>, <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcer</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Respiratory</p></td>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="261880" conceptname="Atelectasis">atelectasis</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccup</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">lung edema</span>, <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disorder</span>, neoplasm, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="253796" conceptname="Pneumothorax">pneumothorax</span>, <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">respiratory disorder</span>, <span class="product-label-link" type="condition" conceptid="260041" conceptname="Candidiasis of lung">respiratory moniliasis</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> increased, <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">voice alteration</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Skin and Appendages</p></td>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="137213" conceptname="Dermal mycosis">fungal dermatitis</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="138102" conceptname="Benign neoplasm of skin">skin benign neoplasm</span>, skin carcinoma, <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorder</span>, skin <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span>, <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulcer</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">vesiculobullous rash</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Nervous</p></td>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypesthesia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">thinking abnormal</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Endocrine</p></td>
<td class="Botrule Rrule"><p class="First">Cushing's syndrome, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, <span class="product-label-link" type="condition" conceptid="138713" conceptname="Disorder of parathyroid gland">parathyroid disorder</span></p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Musculoskeletal</p></td>
<td class="Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">joint disorder</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">myasthenia</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Special Senses</p></td>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">amblyopia</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> (not specified), <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="201577" conceptname="Degenerative and vascular disorders of ear">ear disorder</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear pain</span>, <span class="product-label-link" type="condition" conceptid="433778" conceptname="Orbital hemorrhage">eye hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span> disorder</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_aaf6818a-50e7-4518-97fc-4eb864606f92"></a><a name="section-8.1.2"></a><p></p>
<h3><span class="Bold">Pediatrics</span></h3>
<p class="First">The type and frequency of adverse events in a clinical study in 100 pediatric patients 3 months to 18 years of age dosed with CellCept oral suspension 600 mg/m<span class="Sup">2</span> bid (up to 1 g bid) were generally similar to those observed in adult patients dosed with CellCept capsules at a dose of 1 g bid with the exception of <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, which were observed in a higher proportion in pediatric patients. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a5114c4b-ebd6-4a6e-aa24-cdda1f4376a7"></a><a name="section-8.2"></a><p></p>
<h2>CellCept Intravenous</h2>
<p class="First">The adverse event profile of CellCept Intravenous was determined from a single, double-blind, controlled comparative study of the safety of 2 g/day of intravenous and oral CellCept in renal transplant patients in the immediate posttransplant period (administered for the first 5 days). The potential venous irritation of CellCept Intravenous was evaluated by comparing the adverse events attributable to peripheral venous infusion of CellCept Intravenous with those observed in the intravenous placebo group; patients in this group received active medication by the oral route.</p>
<p>Adverse events attributable to peripheral venous infusion were <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> and <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, both observed at 4% in patients treated with CellCept Intravenous.</p>
<p>In the active controlled study in hepatic transplant patients, 2 g/day of CellCept Intravenous were administered in the immediate posttransplant period (up to 14 days). The safety profile of intravenous CellCept was similar to that of intravenous azathioprine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ARPE"></a><a name="section-8.3"></a><p></p>
<h2>Postmarketing Experience</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a0922672-cdb7-4d7d-8206-90491ccd4a2a"></a><a name="section-8.3.1"></a><p></p>
<p class="First"><span class="Italics">Congenital Disorders</span></p>
<p>Embryofetal Toxicity</p>
<p>Congenital malformations and an increased incidence of first trimester pregnancy loss have been reported following exposure to mycophenolate mofetil during pregnancy (see <span class="Bold"><a href="#PrePreg">PRECAUTIONS: Pregnancy</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9633975d-c31a-4014-906f-4ce529e25332"></a><a name="section-8.3.2"></a><p></p>
<p class="First"><span class="Italics">Digestive</span></p>
<p><span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span> (sometimes caused by cytomegalovirus), <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, isolated cases of intestinal villous <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e77eda74-6791-443e-8295-58d85363bc6e"></a><a name="section-8.3.3"></a><p></p>
<p class="First"><span class="Italics">Hematologic and Lymphatic</span></p>
<p>Cases of pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span> (PRCA) have been reported in patients treated with CellCept in combination with other immunosuppressive agents.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bed13b26-1c28-4a95-ab5d-b6712c1d48af"></a><a name="section-8.3.4"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span> (see <span class="Bold"><a href="#WarnInfections">WARNINGS: Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a>, <a href="#Latent">New or Reactivated <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral Infections</span></a></span>)</p>
<dl>
<dt>•</dt>
<dd>Serious life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> such as <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> and infectious <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> have been reported occasionally.</dd>
<dt>•</dt>
<dd>There is evidence of a higher frequency of certain types of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> such as <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> and <span class="product-label-link" type="condition" conceptid="4008721" conceptname="Atypical mycobacterial infection">atypical mycobacterial infection</span>.</dd>
<dt>•</dt>
<dd>Cases of <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">progressive multifocal leukoencephalopathy</span> (PML), sometimes fatal, have been reported in patients treated with CellCept. The reported cases generally had risk factors for PML, including treatment with immunosuppressant therapies and impairment of immune function.</dd>
<dt>•</dt>
<dd>Polyomavirus associated <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> (PVAN), especially due to BK virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, has been observed in patients receiving immunosuppressants, including CellCept. This <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is associated with serious outcomes, including deteriorating renal function and renal graft loss.</dd>
<dt>•</dt>
<dd>Viral reactivation has been reported in patients infected with HBV or HCV.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c92c2edc-c441-4137-b0c1-dcd46cb4565a"></a><a name="section-8.3.5"></a><p></p>
<p class="First"><span class="Italics">Respiratory</span></p>
<p>Interstitial <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disorders</span>, including fatal <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span>, have been reported rarely and should be considered in the differential diagnosis of pulmonary symptoms ranging from <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> to <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span> in posttransplant patients receiving CellCept.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="OV"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The experience with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of CellCept in humans is very limited. The events received from reports of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> within the known safety profile of the drug. The highest dose administered to renal transplant patients in clinical trials has been 4 g/day. In limited experience with cardiac and hepatic transplant patients in clinical trials, the highest doses used were 4 g/day or 5 g/day. At doses of 4 g/day or 5 g/day, there appears to be a higher rate, compared to the use of 3 g/day or less, of gastrointestinal intolerance (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and/or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>), and occasional hematologic abnormalities, principally <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, leading to a need to reduce or discontinue dosing.</p>
<p>In acute oral toxicity studies, no <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> occurred in adult mice at doses up to 4000 mg/kg or in adult monkeys at doses up to 1000 mg/kg; these were the highest doses of mycophenolate mofetil tested in these species. These doses represent 11 times the recommended clinical dose in renal transplant patients and approximately 7 times the recommended clinical dose in cardiac transplant patients when corrected for BSA. In adult rats, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> occurred after single-oral doses of 500 mg/kg of mycophenolate mofetil. The dose represents approximately 3 times the recommended clinical dose in cardiac transplant patients when corrected for BSA.</p>
<p>MPA and MPAG are usually not removed by hemodialysis. However, at high MPAG plasma concentrations (&gt;100 µg/mL), small amounts of MPAG are removed. By increasing excretion of the drug, MPA can be removed by bile acid sequestrants, such as cholestyramine (see <span class="Bold"><a href="#Pharmacokinetics">CLINICAL PHARMACOLOGY: Pharmacokinetics</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DA"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_832bca71-9bc4-453c-9e98-2432250c079f"></a><a name="section-10.1"></a><p></p>
<h2>Renal Transplantation</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_244f6748-b4c3-415f-a6b0-ec1ce40cb4c0"></a><a name="section-10.1.1"></a><p></p>
<h3><span class="Bold">Adults</span></h3>
<p class="First">A dose of 1 g administered orally or intravenously (over NO LESS THAN 2 HOURS) twice a day (daily dose of 2 g) is recommended for use in renal transplant patients. Although a dose of 1.5 g administered twice daily (daily dose of 3 g) was used in clinical trials and was shown to be safe and effective, no efficacy advantage could be established for renal transplant patients. Patients receiving 2 g/day of CellCept demonstrated an overall better safety profile than did patients receiving 3 g/day of CellCept.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_749467bb-aca6-4a2a-b506-b55f57492f17"></a><a name="section-10.1.2"></a><p></p>
<h3><span class="Bold">Pediatrics (3 months to 18 years of age)</span></h3>
<p class="First">The recommended dose of CellCept oral suspension is 600 mg/m<span class="Sup">2</span> administered twice daily (up to a maximum daily dose of 2 g/10 mL oral suspension). Patients with a body surface area of 1.25 m<span class="Sup">2</span> to 1.5 m<span class="Sup">2</span> may be dosed with CellCept capsules at a dose of 750 mg twice daily (1.5 g daily dose). Patients with a body surface area &gt;1.5 m<span class="Sup">2</span> may be dosed with CellCept capsules or tablets at a dose of 1 g twice daily (2 g daily dose).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_eb136c69-1406-42ed-88f9-e5cabc61cd58"></a><a name="section-10.2"></a><p></p>
<h2>Cardiac Transplantation</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ac194030-902a-4973-8b76-63e6d068c829"></a><a name="section-10.2.1"></a><p></p>
<h3><span class="Bold">Adults</span></h3>
<p class="First">A dose of 1.5 g bid administered intravenously (over NO LESS THAN 2 HOURS) or 1.5 g bid oral (daily dose of 3 g) is recommended for use in adult cardiac transplant patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_27481391-d7a1-47b0-8efd-63cbbed6f62d"></a><a name="section-10.3"></a><p></p>
<h2>Hepatic Transplantation</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_76051b73-4bb0-4fbe-80cb-5f939aacf14c"></a><a name="section-10.3.1"></a><p></p>
<h3><span class="Bold">Adults</span></h3>
<p class="First">A dose of 1 g bid administered intravenously (over NO LESS THAN 2 HOURS) or 1.5 g bid oral (daily dose of 3 g) is recommended for use in adult hepatic transplant patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_79c036ee-25ce-46b7-ac62-fb9f80e3114d"></a><a name="section-10.4"></a><p></p>
<h2>CellCept Capsules, Tablets, and Oral Suspension</h2>
<p class="First">The initial oral dose of CellCept should be given as soon as possible following renal, cardiac or hepatic transplantation. Food had no effect on MPA AUC, but has been shown to decrease MPA C<span class="Sub">max </span>by 40%. Therefore, it is recommended that CellCept be administered on an empty stomach. However, in stable renal transplant patients, CellCept may be administered with food if necessary.</p>
<p>Patients should be instructed to take a missed dose as soon as they remember, except if it is near the next scheduled dose, and then continue to take CellCept at the usual times.</p>
<p><span class="Italics">Note:</span><br>If required, CellCept Oral Suspension can be administered via a nasogastric tube with a minimum size of 8 French (minimum 1.7 mm interior diameter).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6a0c5308-92c7-4d9d-9b2d-1bbdb2dcf7c3"></a><a name="section-10.4.1"></a><p></p>
<h3><span class="Bold">Patients With <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></h3>
<p class="First">No dose adjustments are recommended for renal patients with severe hepatic parenchymal disease. However, it is not known whether dose adjustments are needed for <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> with other etiologies (see <span class="Bold"><a href="#Pharmacokinetics">CLINICAL PHARMACOLOGY: Pharmacokinetics</a></span>).</p>
<p>No data are available for cardiac transplant patients with severe hepatic parenchymal disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b8447e17-eaee-40bd-9782-5ed51653f113"></a><a name="section-10.4.2"></a><p></p>
<h3><span class="Bold">Geriatrics</span></h3>
<p class="First">The recommended oral dose of 1 g bid for renal transplant patients, 1.5 g bid for cardiac transplant patients, and 1 g bid administered intravenously or 1.5 g bid administered orally in hepatic transplant patients is appropriate for elderly patients (see <span class="Bold"><a href="#PreGeriatric">PRECAUTIONS: Geriatric Use</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9e40d8a2-965d-485a-914f-95bde30d37fc"></a><a name="section-10.5"></a><p></p>
<h2>Preparation of Oral Suspension</h2>
<p class="First">It is recommended that CellCept Oral Suspension be constituted by the pharmacist prior to dispensing to the patient.</p>
<p>CellCept Oral Suspension should not be mixed with any other medication.</p>
<p>Mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits. There are no adequate and well-controlled studies in pregnant women (see <span class="Bold"><a href="#Warnings">WARNINGS</a>, <a href="#Precautions">PRECAUTIONS</a>, <a href="#AR">ADVERSE REACTIONS</a>, </span>and<span class="Bold"><a href="#HD"> HANDLING AND DISPOSAL</a></span>). Care should be taken to avoid inhalation or direct contact with skin or mucous membranes of the dry powder or the constituted suspension. If such contact occurs, wash thoroughly with soap and water; rinse eyes with water.</p>
<dl>
<dt>1.</dt>
<dd>Tap the closed bottle several times to loosen the powder.</dd>
<dt>2.</dt>
<dd>Measure 94 mL of water in a graduated cylinder.</dd>
<dt>3.</dt>
<dd>Add approximately half the total amount of water for constitution to the bottle and shake the closed bottle well for about 1 minute.</dd>
<dt>4.</dt>
<dd>Add the remainder of water and shake the closed bottle well for about 1 minute.</dd>
<dt>5.</dt>
<dd>Remove the child-resistant cap and push bottle adapter into neck of bottle.</dd>
<dt>6.</dt>
<dd>Close bottle with child-resistant cap tightly. This will assure the proper seating of the bottle adapter in the bottle and child-resistant status of the cap.</dd>
</dl>
<p>Dispense with patient instruction sheet and oral dispensers. It is recommended to write the date of expiration of the constituted suspension on the bottle label. (The shelf-life of the constituted suspension is 60 days.)</p>
<p>After constitution the oral suspension contains 200 mg/mL mycophenolate mofetil. Store constituted suspension at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). Storage in a refrigerator at 2° to 8°C (36° to 46°F) is acceptable. Do not freeze. Discard any unused portion 60 days after constitution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_94098c83-9671-4cda-8b51-2c0424e893b6"></a><a name="section-10.6"></a><p></p>
<h2>CellCept Intravenous</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_682b0bcc-36ad-4907-a8f7-ef08a39e1e52"></a><a name="section-10.6.1"></a><p></p>
<h3><span class="Bold">Adults</span></h3>
<p class="First">CellCept Intravenous is an alternative dosage form to CellCept capsules, tablets and oral suspension recommended for patients unable to take oral CellCept. CellCept Intravenous should be administered within 24 hours following transplantation. CellCept Intravenous can be administered for up to 14 days; patients should be switched to oral CellCept as soon as they can tolerate oral medication.</p>
<p>CellCept Intravenous must be reconstituted and diluted to a concentration of 6 mg/mL using 5% Dextrose Injection USP. CellCept Intravenous is incompatible with other intravenous infusion solutions. Following reconstitution, CellCept Intravenous must be administered by slow intravenous infusion over a period of NO LESS THAN 2 HOURS by either peripheral or central vein.</p>
<p>CAUTION: CELLCEPT INTRAVENOUS SOLUTION SHOULD NEVER BE ADMINISTERED BY RAPID OR BOLUS INTRAVENOUS INJECTION (see <span class="Bold"><a href="#Warnings">WARNINGS</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6f74c8dd-2a6f-4c5b-b5cb-41a261167bfa"></a><a name="section-10.7"></a><p></p>
<h2>Preparation of Infusion Solution (6 mg/mL)</h2>
<p class="First">Caution should be exercised in the handling and preparation of solutions of CellCept Intravenous. Avoid direct contact of the prepared solution of CellCept Intravenous with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water; rinse eyes with plain water (see <span class="Bold"><a href="#Warnings">WARNINGS</a>, <a href="#Precautions">PRECAUTIONS</a>, <a href="#AR">ADVERSE REACTIONS</a>, </span>and<span class="Bold"><a href="#HD"> HANDLING AND DISPOSAL</a></span>).</p>
<p>CellCept Intravenous does not contain an antibacterial preservative; therefore, reconstitution and dilution of the product must be performed under aseptic conditions. Additionally, this product is sealed under vacuum and should retain a vacuum throughout its shelf life. If a lack of vacuum in the vial is noted while adding diluent, the vial should not be used.</p>
<p>CellCept Intravenous infusion solution must be prepared in two steps: the first step is a reconstitution step with 5% Dextrose Injection USP, and the second step is a dilution step with 5% Dextrose Injection USP. A detailed description of the preparation is given below:</p>
<p>Step 1</p>
<dl>
<dt>•</dt>
<dd>Two (2) vials of CellCept Intravenous are used for preparing each 1 g dose, whereas three (3) vials are needed for each 1.5 g dose. Reconstitute the contents of each vial by injecting 14 mL of 5% Dextrose Injection USP.</dd>
<dt>•</dt>
<dd>Gently shake the vial to dissolve the drug.</dd>
<dt>•</dt>
<dd>Inspect the resulting slightly yellow solution for particulate matter and discoloration prior to further dilution. Discard the vials if particulate matter or discoloration is observed.</dd>
</dl>
<p>Step 2</p>
<dl>
<dt>•</dt>
<dd>To prepare a 1 g dose, further dilute the contents of the two reconstituted vials (approx. 2 × 15 mL) into 140 mL of 5% Dextrose Injection USP. To prepare a 1.5 g dose, further dilute the contents of the three reconstituted vials (approx. 3 × 15 mL) into 210 mL of 5% Dextrose Injection USP. The final concentration of both solutions is 6 mg mycophenolate mofetil per mL.</dd>
<dt>•</dt>
<dd>Inspect the infusion solution for particulate matter or discoloration. Discard the infusion solution if particulate matter or discoloration is observed.</dd>
</dl>
<p>If the infusion solution is not prepared immediately prior to administration, the commencement of administration of the infusion solution should be within 4 hours from reconstitution and dilution of the drug product. Keep solutions at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F).</p>
<p>CellCept Intravenous should not be mixed or administered concurrently via the same infusion catheter with other intravenous drugs or infusion admixtures.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_676d02f2-b3bf-4e9a-8a5a-fb11259605d8"></a><a name="section-10.8"></a><p></p>
<h2>Dosage Adjustments</h2>
<p class="First">In renal transplant patients with severe <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic renal impairment</span> (GFR &lt;25 mL/min/1.73 m<span class="Sup">2</span>) outside the immediate posttransplant period, doses of CellCept greater than 1 g administered twice a day should be avoided. These patients should also be carefully observed. No dose adjustments are needed in renal transplant patients experiencing delayed graft function postoperatively (see <span class="Bold"><a href="#Pharmacokinetics">CLINICAL PHARMACOLOGY: Pharmacokinetics </a></span>and<span class="Bold"><a href="#PreRenal"> PRECAUTIONS: Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></span>).</p>
<p>No data are available for cardiac or hepatic transplant patients with severe <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic renal impairment</span>. CellCept may be used for cardiac or hepatic transplant patients with severe <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic renal impairment</span> if the potential benefits outweigh the potential risks.</p>
<p>If <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> develops (ANC &lt;1.3 × 10<span class="Sup">3</span>/µL), dosing with CellCept should be interrupted or the dose reduced, appropriate diagnostic tests performed, and the patient managed appropriately (see <span class="Bold"><a href="#WarnNeutropenia">WARNINGS: <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></a>, <a href="#AR">ADVERSE REACTIONS</a>, </span>and<span class="Bold"><a href="#PreLT"> PRECAUTIONS: Laboratory Tests</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="HD"></a><a name="section-11"></a><p></p>
<h1>HANDLING AND DISPOSAL</h1>
<p class="First">Mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits (see <span class="Bold"><a href="#PrePreg">Pregnancy</a> and <a href="#WarnET">WARNINGS: Embryofetal Toxicity</a></span>). CellCept tablets should not be crushed and CellCept capsules should not be opened or crushed. Avoid inhalation or direct contact with skin or mucous membranes of the powder contained in CellCept capsules and CellCept Oral Suspension (before or after constitution). If such contact occurs, wash thoroughly with soap and water; rinse eyes with plain water. Should a spill occur, wipe up using paper towels wetted with water to remove spilled powder or suspension. Caution should be exercised in the handling and preparation of solutions of CellCept Intravenous. Avoid direct contact of the prepared solution of CellCept Intravenous with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water; rinse eyes with plain water.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="HS"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_aa1686bf-2bed-44f0-aef1-cb8553e10079"></a><a name="section-12.1"></a><p></p>
<h2>CellCept (mycophenolate mofetil capsules) 250 mg</h2>
<p class="First"> Blue-brown, two-piece hard gelatin capsules, printed in black with "CellCept 250" on the blue cap and "Roche" on the brown body. Supplied in the following presentations:</p>
<table width="70%">
<col width="35%">
<col width="35%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="top"><span class="Bold">NDC Number</span></th>
<th class="Botrule Toprule" align="left" valign="top"><span class="Bold">Size</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First">NDC 0004-0259-01</p></td>
<td class="Toprule"><p class="First">Bottle of 100</p></td>
</tr>
<tr>
<td><p class="First">NDC 0004-0259-05</p></td>
<td><p class="First">Package containing 12 bottles of 120</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">NDC 0004-0259-43</p></td>
<td class="Botrule"><p class="First">Bottle of 500</p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="ID_8347da11-fcff-460b-b3bc-7a0bd5718c4c"></a><a name="section-12.1.1"></a><p></p>
<h3><span class="Bold">Storage</span></h3>
<p class="First">Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0a430cc9-c692-4d8e-a4e5-40967c7fbb74"></a><a name="section-12.2"></a><p></p>
<h2>CellCept (mycophenolate mofetil tablets) 500 mg</h2>
<p class="First"> Lavender-colored, caplet-shaped, film-coated tablets printed in black with "CellCept 500" on one side and "Roche" on the other. Supplied in the following presentations:</p>
<table width="70%">
<col width="36%">
<col width="35%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="top"><span class="Bold">NDC Number</span></th>
<th class="Botrule Toprule" align="left" valign="top"><span class="Bold">Size</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First">NDC 0004-0260-01</p></td>
<td class="Toprule"><p class="First">Bottle of 100</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">NDC 0004-0260-43</p></td>
<td class="Botrule"><p class="First">Bottle of 500</p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="ID_207272cd-07cf-4a1d-8ee3-3ad609a5d7d3"></a><a name="section-12.2.1"></a><p></p>
<h3><span class="Bold">Storage and Dispensing Information</span></h3>
<p class="First">Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). Dispense in light-resistant containers, such as the manufacturer's original containers.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d5674af2-2316-4fbb-94a8-2d3d64caf120"></a><a name="section-12.3"></a><p></p>
<h2>CellCept Oral Suspension (mycophenolate mofetil for oral suspension)</h2>
<p class="First">Supplied as a white to off-white powder blend for constitution to a white to off-white mixed-fruit flavor suspension. Supplied in the following presentation:</p>
<table width="70%">
<col width="35%">
<col width="35%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="top"><span class="Bold">NDC Number</span></th>
<th class="Botrule Toprule" align="left" valign="top"><span class="Bold">Size</span></th>
</tr></thead>
<tbody><tr class="First Last">
<td class="Botrule Toprule"><p class="First">NDC 0004-0261-29</p></td>
<td class="Botrule Toprule"><p class="First">225 mL bottle with bottle adapter and 2 oral dispensers</p></td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="ID_8fe855c6-e837-4f19-bfcd-fff9f8a9459b"></a><a name="section-12.3.1"></a><p></p>
<h3><span class="Bold">Storage</span></h3>
<p class="First">Store dry powder at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). Store constituted suspension at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) for up to 60 days. Storage in a refrigerator at 2° to 8°C (36° to 46°F) is acceptable. Do not freeze.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_972e4cf9-2a9c-4d26-8399-28da195498ae"></a><a name="section-12.4"></a><p></p>
<h2>CellCept Intravenous (mycophenolate mofetil hydrochloride for injection)</h2>
<p class="First">Supplied in a 20 mL, sterile vial containing the equivalent of 500 mg mycophenolate mofetil as the hydrochloride salt in cartons of 4 vials:</p>
<table width="35%">
<col width="35%">
<thead><tr class="First Last"><th class="Botrule Toprule" align="left" valign="top"><span class="Bold">NDC Number</span></th></tr></thead>
<tbody><tr class="First Last"><td class="Botrule Toprule"><p class="First">NDC 0004-0298-09</p></td></tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="ID_144d9b22-7c91-4878-8742-cc495bd0deeb"></a><a name="section-12.4.1"></a><p></p>
<h3><span class="Bold">Storage</span></h3>
<p class="First">Store powder and reconstituted/infusion solutions at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6a629a12-3b3e-40e9-b8f2-b53a14488f27"></a><a name="section-13"></a><p></p>
<p class="First">PI Revised: September 2013</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="MG"></a><a name="section-14"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<p class="First"><span class="Bold">CellCept<span class="Sup">®</span> [SEL-sept]</span><br><span class="Bold"> (mycophenolate mofetil capsules)</span><br><span class="Bold">(mycophenolate mofetil tablets)</span></p>
<p><span class="Bold">CellCept<span class="Sup">®</span> Oral Suspension</span><br><span class="Bold">(mycophenolate mofetil for oral suspension)</span></p>
<p><span class="Bold">CellCept<span class="Sup">®</span> Intravenous</span><br><span class="Bold">(mycophenolate mofetil hydrochloride for injection)</span></p>
<p>Read the Medication Guide that comes with CellCept before you start taking it and each time you refill your prescription. There may be new information. This Medication Guide does not take the place of talking with your doctor about your medical condition or your treatment.</p>
<p><span class="Bold">What is the most important information I should know about CellCept?</span></p>
<p><span class="Bold">CellCept can cause serious side effects:</span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Increased risk of loss of a pregnancy (<span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span>) and higher risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. </span>Females who take CellCept during pregnancy have a higher risk of <span class="Bold"><span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span></span> during the first 3 months (first trimester), and a higher risk that their baby will be born with <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>.<br> If you are a female who can become pregnant <dl>
<dt>•</dt>
<dd>your doctor must talk with you about acceptable birth control methods (contraceptive counseling) to use while taking CellCept.</dd>
<dt>•</dt>
<dd>you should have one pregnancy test immediately before starting CellCept and another pregnancy test  8 to 10 days later. Pregnancy tests should be repeated during routine follow-up visits with your doctor. Talk to your doctor about the results of all of your pregnancy tests.</dd>
<dt>•</dt>
<dd>you must use acceptable birth control during your entire CellCept therapy and for 6 weeks after stopping CellCept, unless at any time you choose to avoid sexual intercourse (abstinence) with a man completely.<br><br>CellCept decreases blood levels of the hormones in birth control pills that you take by mouth. Birth control pills may not work as well while you take CellCept, and you could become pregnant. If you take birth control pills while using CellCept you must also use another form of birth control.  Talk to your doctor about other birth control methods that you can use while taking CellCept.<br><br>If you plan to become pregnant, talk with your doctor. Your doctor will decide if other medicines to prevent rejection may be right for you.<br><br><span class="Bold">If you become pregnant while taking CellCept, <span class="Underline">do not</span> stop taking CellCept. Call your doctor right away. </span>In certain situations, you and your doctor may decide that taking CellCept is more important to your health than the possible risks to your unborn baby.The purpose of this registry is to gather information about the health of you and your baby.<dl>
<dt>•</dt>
<dd>You and your doctor should report your pregnancy to<dl>
<dt>•</dt>
<dd>Mycophenolate Pregnancy Registry (1-800-617-8191)</dd>
</dl>
</dd>
</dl>
</dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">Increased risk of getting serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. </span>CellCept weakens the body's immune system and affects your ability to fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can happen with CellCept and can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. These serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can include: <dl>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral infections</span>.</span> Certain viruses can live in your body and cause active <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> when your immune system is weak. <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral infections</span> that can happen with CellCept include:                               <dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Shingles</span>, other <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes infections</span>, and cytomegalovirus (CMV). CMV can cause serious tissue and blood <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</dd>
<dt>•</dt>
<dd>BK virus. BK virus can affect how your kidney works and cause your transplanted kidney to fail.</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B and C viruses.  <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> viruses can affect how your liver works. Talk to your doctor about how <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> viruses may affect you.</dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">A brain <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> called <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">Progressive Multifocal Leukoencephalopathy</span> (PML). </span>In some patients, CellCept may cause an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> of the brain that may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. You are at risk for this brain <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> because you have a weakened immune system. You should tell your doctor right away if you have any of the following symptoms: <dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span> on one side of the body</dd>
<dt>•</dt>
<dd>You do not care about things that you usually care about (<span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>)</dd>
<dt>•</dt>
<dd>You are <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span> or have problems thinking</dd>
<dt>•</dt>
<dd>You can not control your muscles</dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal infections</span>. </span>Yeasts and other types of <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> can happen with CellCept and can cause serious tissue and blood <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (see <span class="Bold">"<a href="#_RefSE">What are the possible side effects of CellCept?</a>"</span>)</dd>
</dl>
</dd>
</dl>
<p><span class="Bold">Call your doctor right away if you have any of the following signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>: </span></p>
<dl>
<dt>•</dt>
<dd>Temperature of 100.5°F or greater</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Cold symptoms</span>, such as a <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span> or <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu symptoms</span>, such as an <span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">Earache</span> or <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> during urination</dd>
<dt>•</dt>
<dd>White patches in the mouth or throat</dd>
<dt>•</dt>
<dd>Unexpected <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></dd>
<dt>•</dt>
<dd>Cuts, scrapes or incisions that are red, warm and oozing pus</dd>
<dt>•</dt>
<dd>
<span class="Bold">Increased risk of getting certain cancers. </span>People who take CellCept have a higher risk of getting <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, and other cancers, especially skin cancer. Tell your doctor if you have: <dl>
<dt>•</dt>
<dd>unexplained <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, prolonged <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> or lymph node <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></dd>
<dt>•</dt>
<dd>a brown or black <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesion</span> with uneven borders, or one part of the lesion does not look like the other</dd>
<dt>•</dt>
<dd>a change in the size and color of a mole</dd>
<dt>•</dt>
<dd>a new <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesion</span> or bump</dd>
<dt>•</dt>
<dd>any other changes to your health</dd>
</dl>
</dd>
</dl>
<p><span class="Bold">See the section "<a href="#_RefSE">What are the possible side effects of CellCept?</a>" for information about other serious side effects.</span></p>
<p><span class="Bold">What is CellCept?</span></p>
<p>CellCept is a prescription medicine to prevent rejection (antirejection medicine) in people who have received a kidney, heart or liver transplant. Rejection is when the body's immune system perceives the new organ as a "foreign" threat and attacks it.</p>
<p>CellCept is used with other medicines called cyclosporine (Sandimmune<span class="Sup">®</span>, Gengraf<span class="Sup">®</span>, Neoral<span class="Sup">®</span>) and corticosteroids.</p>
<p>CellCept has been used safely and works in children who received a kidney transplant as it does in adults. It is not known if CellCept is safe and works in children who receive a heart or liver transplant. </p>
<p><span class="Bold">Who should not take CellCept? </span></p>
<p><span class="Bold">Do not take CellCept if you are allergic to mycophenolate mofetil or any of the ingredients in CellCept. </span>See the end of this Medication Guide for a complete list of ingredients in CellCept.</p>
<p><span class="Bold">What should I tell my doctor before taking CellCept?</span></p>
<p>Tell your doctor about all of your medical conditions, if you:</p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">have any digestive problems,</span> such as <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>.</dd>
<dt>•</dt>
<dd>
<span class="Bold">have <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">Phenylketonuria</span> (PKU).</span> CellCept oral suspension contains aspartame (a source of phenylalanine).</dd>
<dt>•</dt>
<dd>
<span class="Bold">have Lesch-Nyhan or Kelley-Seegmiller syndrome or another rare inherited deficiency hypoxanthine-guanine phosphoribosyl-transferase (HGPRT).</span> You should not take CellCept if you have one of these disorders.</dd>
<dt>•</dt>
<dd>
<span class="Bold">plan to receive any vaccines. People taking CellCept should not take live vaccines. </span>Some vaccines may not work as well during treatment with CellCept.</dd>
<dt>•</dt>
<dd>
<span class="Bold">are pregnant or are planning to become pregnant. </span>See <span class="Bold">"<a href="#_RefImportant">What is the most important information I should know about CellCept?</a>"</span>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">are breastfeeding or plan to breastfeed. </span>It is not known if CellCept passes into breast milk. You and your doctor will decide if you will take CellCept or breastfeed.</dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about all of the medicines you are taking including prescription and nonprescription medicines, vitamins and herbal supplements.</span> Some medicines may affect the way CellCept works, and CellCept may affect how some medicines work. Especially tell your doctor if you take:</p>
<dl>
<dt>•</dt>
<dd>birth control pills (oral contraceptives). See<span class="Bold"> "<a href="#_RefImportant">What is the most important information I should know about CellCept?</a>"</span>
</dd>
<dt>•</dt>
<dd>sevelamer (Renagel<span class="Sup">®</span>, Renvela™). These products should be taken 2 hours after taking CellCept</dd>
<dt>•</dt>
<dd>acyclovir (Zovirax<span class="Sup">®</span>), valacyclovir (Valtrex<span class="Sup">®</span>), ganciclovir (CYTOVENE<span class="Sup">®</span>-IV, Vitrasert<span class="Sup">®</span>), valganciclovir (VALCYTE<span class="Sup">®</span>)</dd>
<dt>•</dt>
<dd>rifampin (Rifater<span class="Sup">®</span>, Rifamate<span class="Sup">®</span>, Rimactane<span class="Sup">®</span>, Rifadin<span class="Sup">®</span>)</dd>
<dt>•</dt>
<dd>antacids that contain magnesium and aluminum (CellCept and the antacid should not be taken at the same time)</dd>
<dt>•</dt>
<dd>proton pump inhibitors (PPIs) (Prevacid<span class="Sup">®</span>, Protonix<span class="Sup">®</span>)</dd>
<dt>•</dt>
<dd>sulfamethoxazole/trimethoprim (BACTRIM™, BACTRIM DS™)</dd>
<dt>•</dt>
<dd>norfloxacin (Noroxin<span class="Sup">®</span>) and metronidazole (Flagyl<span class="Sup">®</span>, Flagyl<span class="Sup">®</span> ER, Flagyl<span class="Sup">®</span> IV, Metro IV, Helidac<span class="Sup">®</span>, Pylera™)</dd>
<dt>•</dt>
<dd>ciprofloxacin (Cipro<span class="Sup">®</span>, Cipro<span class="Sup">®</span> XR, Ciloxan<span class="Sup">®</span>, Proquin<span class="Sup">®</span> XR) and amoxicillin plus clavulanic acid (Augmentin<span class="Sup">®</span>, Augmentin XR™)</dd>
<dt>•</dt>
<dd>azathioprine (Azasan<span class="Sup">®</span>, Imuran<span class="Sup">®</span>)</dd>
<dt>•</dt>
<dd>cholestyramine (Questran Light<span class="Sup">®</span>, Questran<span class="Sup">®</span>, Locholest Light, Locholest, Prevalite<span class="Sup">®</span>)</dd>
</dl>
<p>Know the medicines you take. Keep a list of them to show to your doctor or nurse and pharmacist when you get a new medicine. Do not take any new medicine without talking with your doctor.</p>
<p><span class="Bold">How should I take CellCept?</span></p>
<dl>
<dt>•</dt>
<dd>Take CellCept exactly as prescribed.</dd>
<dt>•</dt>
<dd>Do not stop taking CellCept or change the dose unless your doctor tells you to.</dd>
<dt>•</dt>
<dd>If you miss a dose of CellCept, or are not sure when you took your last dose, take the regular amount of CellCept prescribed as soon as you remember. If it is time for your next dose, skip the missed dose and take your next dose at your normal scheduled time. Do not take 2 doses at the same time. Call your doctor if you are not sure what to do.</dd>
<dt>•</dt>
<dd>Take CellCept capsules, tablets and oral suspension on an empty stomach, either 1 hour before or 2 hours after a meal, unless your healthcare provider tells you otherwise. With the approval of your healthcare provider, in stable kidney transplant patients, CellCept can be taken with food if necessary.</dd>
<dt>•</dt>
<dd>Most people take CellCept by mouth either as blue and brown capsules or lavender tablets. Some people may get CellCept soon after their transplant surgery as an infusion into a vein.</dd>
<dt>•</dt>
<dd>Do not crush CellCept tablets. Do not open or crush CellCept capsules.</dd>
<dt>•</dt>
<dd>If you are not able to swallow CellCept tablets or capsules, your doctor may prescribe CellCept Oral Suspension. This is a liquid form of CellCept. Your pharmacist will mix the medicine before giving it to you.</dd>
<dt>•</dt>
<dd>Do not mix CellCept Oral Suspension with any other medicine.</dd>
<dt>•</dt>
<dd>If you take too much CellCept, call your doctor or the poison control center right away.</dd>
</dl>
<p><span class="Bold">What should I avoid while taking CellCept?</span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Avoid pregnancy. </span>See<span class="Bold"> "<a href="#_RefImportant">What is the most important information I should know about CellCept?</a>" </span>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">Limit the amount of time you spend in sunlight. </span>Avoid using tanning beds or sunlamps. People who take CellCept have a higher risk of getting skin cancer. (See<span class="Bold"> "<a href="#_RefImportant">What is the most important information I should know about CellCept?</a>"</span>) Wear protective clothing when you are in the sun and use a sunscreen with a high protection factor (SPF 30 and above). This is especially important if your skin is very fair or if you have a family history of skin cancer.</dd>
</dl>
<p><span class="Bold">What are the possible side effects of CellCept?</span></p>
<p><span class="Bold">CellCept can cause serious side effects: </span></p>
<dl>
<dt>•</dt>
<dd>See<span class="Bold"> "<a href="#_RefImportant">What is the most important information I should know about CellCept?</a>"</span>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">Low blood cell counts.</span> People taking high doses of CellCept each day may have a decrease in blood counts, including <dl>
<dt>•</dt>
<dd>
<span class="Bold">white blood cells, especially <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>.</span> <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span> fight against <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. You have a higher chance of getting an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> when your white blood cell count is low. This is most common from 3 months to 6 months after your transplant.</dd>
<dt>•</dt>
<dd>
<span class="Bold">red blood cells.</span> Red blood cells carry oxygen to your body tissues. You have a higher chance of getting severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> when your red blood cell count is low.</dd>
<dt>•</dt>
<dd>
<span class="Bold">platelets</span>. Platelets help with blood clotting.</dd>
</dl>
</dd>
<dt> </dt>
<dd> </dd>
<dt> </dt>
<dd>Your doctor will do blood tests before you start taking CellCept and during treatment with CellCept to check your blood cell counts.<br><br>Tell your doctor right away if you have any signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (see <span class="Bold">"<a href="#_RefImportant">What is the most important information I should know about CellCept?</a>"</span>), or any unexpected <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Also, tell your doctor if you have unusual <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, lack of energy, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>.</dd>
</dl>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Stomach problems. </span>Stomach and intestinal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can happen in people who take high doses of CellCept. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> can be severe and you may have to be hospitalized for treatment.</dd>
</dl>
<p><span class="Bold">Common side effects include: </span></p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Call your doctor right away if you have <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Do not stop taking CellCept without first talking with your doctor.</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></dd>
<dt>•</dt>
<dd>stomach area <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the lower legs, ankles and feet</dd>
<dt>•</dt>
<dd>high blood pressure</dd>
</dl>
<p>Side effects that happen more often in children than in adults taking CellCept include:</p>
<table width="100%">
<col width="50%">
<col width="50%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Toprule"><dl>
<dt>•</dt>
<dd>stomach area <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></dd>
<dt>•</dt>
<dd>blood <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (<span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
</dl></td>
<td class="Botrule Toprule"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">colds</span> (<span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infections</span>)</dd>
<dt>•</dt>
<dd>high blood pressure</dd>
<dt>•</dt>
<dd>low white blood cell count</dd>
<dt>•</dt>
<dd>low red blood cell count</dd>
</dl></td>
</tr></tbody>
</table>
<p>These are not all of the possible side effects of CellCept. Tell your doctor about any side effect that bothers you or that does not go away. </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or to Genentech at 1-888-835-2555.</p>
<p><span class="Bold">How should I store CellCept?</span></p>
<dl>
<dt>•</dt>
<dd>Store CellCept capsules and tablets at room temperature, between 59°F to 86°F (15°C to 30°C). Keep the container closed tightly.</dd>
<dt>•</dt>
<dd>Store the prepared CellCept Oral Suspension at room temperature, between 59°F to 86°F (15°C to 30°C), for up to 60 days. You can also store CellCept Oral Suspension in the refrigerator at 36°F to 46°F (2°C to 8°C). <span class="Bold">Do not freeze CellCept Oral Suspension.</span>
</dd>
<dt>•</dt>
<dd><span class="Bold">Keep CellCept and all medicines out of the reach of children </span></dd>
</dl>
<p><span class="Bold">General Information about CellCept</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use CellCept for a condition for which it was not prescribed. Do not give CellCept to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about CellCept. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about CellCept that is written for healthcare professionals. For more information, call 1-888-835-2555 or visit www.gene.com/gene/products/information/cellcept.</p>
<p><span class="Bold">What are the ingredients in CellCept?</span></p>
<p><span class="Bold">Active Ingredient:</span> mycophenolate mofetil</p>
<p><span class="Bold">Inactive Ingredients:</span></p>
<p><span class="Underline">CellCept 250 mg capsules:</span> croscarmellose sodium, magnesium stearate, povidone (K-90) and pregelatinized starch. The capsule shells contain black iron oxide, FD&amp;C blue #2, gelatin, red iron oxide, silicon dioxide, sodium lauryl sulfate, titanium dioxide, and yellow iron oxide.</p>
<p><span class="Underline">CellCept 500 mg tablets:</span> black iron oxide, croscarmellose sodium, FD&amp;C blue #2 aluminum lake, hydroxypropyl cellulose, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol 400, povidone (K-90), red iron oxide, talc, and titanium dioxide; may also contain ammonium hydroxide, ethyl alcohol, methyl alcohol, n-butyl alcohol, propylene glycol, and shellac.</p>
<p><span class="Underline">CellCept Oral Suspension:</span> aspartame, citric acid anhydrous, colloidal silicon dioxide, methylparaben, mixed fruit flavor, sodium citrate dihydrate, sorbitol, soybean lecithin, and xanthan gum.</p>
<p><span class="Underline">CellCept Intravenous:</span> polysorbate 80, and citric acid. Sodium hydroxide may have been used in the manufacture of CellCept Intravenous to adjust the pH. </p>
<p>This Medication Guide has been approved by the US Food and Drug Administration.</p>
<p>CELLCEPT, CYTOVENE-IV, and VALCYTE are registered trademarks of Hoffmann-La Roche Inc.<br>BACTRIM and BACTRIM DS are trademarks of Hoffmann-La Roche Inc.</p>
<p>Distributed by:<br><br><span class="Bold">Genentech USA, Inc.</span><br>A Member of the Roche Group<br>1 DNA Way<br>South San Francisco, CA 94080-4990</p>
<p>MG Revised: September 2013</p>
<p>For additional copies of this Medication Guide, please call 1-800-617-8191 or visit www.gene.com/gene/products/information/cellcept. </p>
<p>© 2013 Genentech, Inc. All rights reserved.</p>
<p>Representative sample of labeling (see the <a href="#HS">HOW SUPPLIED</a> section for complete listing):</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_9881b8c9-8df6-4268-9e6b-5b91b4bf7d19"></a><a name="section-15"></a><p></p>
<h1>Package/Label Display Panel</h1>
<p class="First">CellCept®</p>
<p>(mycophenolate mofetil capsules)</p>
<p>250 mg</p>
<p>100 capsules</p>
<div class="Figure">
<a name="id-1329438024"></a><img alt="carton label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=81ca6530-76d1-46f1-9bf8-0ffac79d2523&amp;name=image-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_0625e756-79a5-4e75-8097-bc853a0c991f"></a><a name="section-16"></a><p></p>
<h1>Package/Label Display Panel</h1>
<p class="First">CellCept®</p>
<p>(mycophenolate mofetil capsule)</p>
<p>250 mg</p>
<div class="Figure">
<a name="id1311527386"></a><img alt="pouch" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=81ca6530-76d1-46f1-9bf8-0ffac79d2523&amp;name=image-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_5d940cd3-9c68-44e0-9640-6b27d0514b8c"></a><a name="section-17"></a><p></p>
<h1>Package/Label Display Panel</h1>
<p class="First">CellCept® 250 mg</p>
<p>Mycophenolate Mofetil Capsules</p>
<p>10 Capsules</p>
<div class="Figure">
<a name="id1376818207"></a><img alt="bag label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=81ca6530-76d1-46f1-9bf8-0ffac79d2523&amp;name=image-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CELLCEPT 		
					</strong><br><span class="contentTableReg">mycophenolate mofetil capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-3122(NDC:0004-0259)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Mycophenolate mofetil</strong> (mycophenolic acid) </td>
<td class="formItem">Mycophenolate mofetil</td>
<td class="formItem">250 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>povidone K90</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferrosoferric oxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C blue no. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide yellow</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE, BROWN</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">CellCept;250;Roche</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-3122-4</td>
<td class="formItem">100  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-3122-6</td>
<td class="formItem">1  in 1 POUCH; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:55154-3122-0</td>
<td class="formItem">10  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050722</td>
<td class="formItem">05/03/1995</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cardinal Health
							(188557102)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cardinal Health</td>
<td class="formItem"></td>
<td class="formItem">188557102</td>
<td class="formItem">REPACK(55154-3122)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>563ce861-c94f-4482-bc10-4ff80698ceec</div>
<div>Set id: 81ca6530-76d1-46f1-9bf8-0ffac79d2523</div>
<div>Version: 6</div>
<div>Effective Time: 20150318</div>
</div>
</div> <div class="DistributorName">Cardinal Health</div></p>
</body></html>
